Development and assessment of a machine learning tool for predicting emergency admission in Scotland

James Liley^{1,2,3,*,⊥}, Gergo Bohner^{1,4,*}, Samuel R. Emerson³, Bilal A. Mateen^{1,5}, Katie Borland⁶, David Carr⁶, Scott Heald⁶, Samuel D. Oduro^{6b}, Jill Ireland⁶, Keith Moffat^{6,7}, Rachel Porteous⁶, Stephen Riddell^{6b}, Simon Rogers⁸, Ioanna Thoma^{1,2}, Nathan Cunningham^{1,9}, Chris Holmes^{1,10}, Katrina Payne¹, Sebastian J. Vollmer^{1,4}, Catalina A. Vallejos^{1,2,⊥}, and Louis J. M. Aslett^{1,3,⊥}

¹Alan Turing Institute, London, UK ²MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK

³Department of Mathematical Sciences, Durham University, UK

⁴Mathematics Institute, University of Warwick, UK

⁵Institute of Health Informatics, University College London, UK, and

Wellcome Trust, London, UK

⁶Public Health Scotland (PHS). (b): former employee

⁷University of St Andrews, UK

⁸NHS National Services Scotland, UK

⁹Department of Statistics, University of Warwick, UK

¹⁰Department of Statistics, University of Oxford, UK

*Equal contribution

[⊥]Corresponding

December 11, 2023

Abstract

Emergency admissions (EA), where a patient requires urgent in-hospital care, are a major challenge for healthcare systems. The development of risk prediction models can partly alleviate this problem by supporting primary care interventions and public health planning. Here, we introduce SPARRAv4, a predictive score for EA risk that will be deployed nationwide in Scotland. SPARRAv4 was derived using supervised and unsupervised machine-learning methods applied to routinely collected electronic health records from approximately 4.8M Scottish residents (2013-18). We demonstrate improvements in discrimination and calibration with respect to previous scores deployed in Scotland, as well as stability over a 3-year timeframe. Our analysis also provides insights about the epidemiology of EA risk in Scotland, by studying predictive performance across different population sub-groups and reasons for admission, as well as by quantifying the effect of individual input features. Finally, we discuss broader challenges including reproducibility and how to safely update risk prediction models that are already deployed at population level.

Introduction

Emergency admissions (EA), where a patient requires urgent in-hospital care, represent deteriorations in individual health and are a major challenge for healthcare systems. For example, approximately 395,000 Scottish residents (≈1 in 14) had at least one EA between 1 April 2021 and 31 March 2022 [Public Health Scotland, 2022]. In total, around 600,000 EAs were recorded for these individuals, nearly 54% of all hospital admissions in that period, and they resulted in longer hospital stays (6.8 days average) compared to planned elective admissions (3.6 days average). Modern health and social care policies aim to implement proactive strategies [Rural Access Action Team, 2005], often by appropriate primary care intervention [McDonagh et al., 2000, Sanderson and Dixon, 2000, Coast et al., 1996]. Machine learning (ML) can support such interventions by identifying individuals at risk of EA who may benefit from anticipatory care. If successful, such interventions can be expected to improve patient outcomes and reduced pressures on secondary care (Figure 1A).

A range of risk prediction models have been developed in this context [Rahimian et al., 2018, Lyon et al., 2007, Wallace et al., 2014, Bottle et al., 2006, Billings et al., 2006, Hippisley-Cox and Coupland, 2013. However, transferability across temporal and geographical settings is limited due to differing demographics and data availability [Wallace et al., 2014. Development of models in the setting in which they will be used is thus preferable to reapplication of models trained in other settings. In Scotland, the Information Services Division of the National Services Scotland (now incorporated into Public Health Scotland; PHS) developed SPARRA (Scottish Patients At Risk of Re-admission and Admission) — an algorithm to predict the risk of EA in the next 12 months. SPARRA was derived using national electronic health records (EHR) databases and has been in use since 2006. The current version of the algorithm (SPARRAv3) [Health and Social Care Information Programme, 2011 was deployed in 2012/13 and is calculated monthly by PHS for almost the entire Scottish population. Individual-level SPARRA scores can be accessed by general practitioners (GPs), helping them to plan mitigation strategies for individuals with complex care needs. Collectively, SPARRA scores may be used to estimate future demand, supporting planning and resource allocation. SPARRA has also been used extensively in public health research [Leckcivilize et al., 2021, Highet et al., 2014, Bajaj et al., 2016, Canny et al., 2016, Manoukian et al., 2021, Wallace et al., 2016].

In this paper we update the SPARRA algorithm to version 4 (SPARRAv4) using contemporary supervised and unsupervised ML methods. In particular, we use an ensemble of machine learning methods [Van der Laan et al., 2007], and use a topic model [Blei et al., 2003 to derive further information from prescriptions and diagnostic data. This represents a large scale ML risk score, fitted and deployed at national level, and widely available in clinical settings. We develop SPARRAv4 using EHRs collected for around 4.8 million (after exclusions) Scottish residents between 2013 and 2018. Among other variables, this includes data about past hospital admissions, long term conditions (e.g. asthma) and prescriptions. We use cross-validation to evaluate the validity of SPARRAv4 and its stability over time. This shows an improvement of performance with respect to SPARRAv3 in terms of discrimination and calibration, including a stratified analysis across different subpopulations. We also perform extensive analyses to determine what reasons for emergency admission are predictable, and use Shaplev values [Lundberg and Lee, 2017] to quantify the effect of individual input factors. Finally, we discuss some of the practical challenges that arise when developing and deploying models of this kind, including issues associated to updating risk scores that are already deployed at population level.

Reproducibility is critical to ensure reliable application of ML in clinical settings [Mc-Dermott et al., 2021]. To provide a transparent description of our pipeline, this manuscript conforms to the TRIPOD guidelines [Collins et al., 2015] (S1). Moreover, all code is publicly available at github.com/jamesliley/SPARRAv4. This includes non-disclosive outputs used to generate all the figures and tables presented in this article.

Results

Data overview

The input data prior to any exclusions combines multiple national EHR databases held by Public Health Scotland for 5.8 million Scottish residents between 1 May 2013 and 30 April 2018 (Supplementary Table S2), some of whom died during the observation period. These comprised 468 million records, comprising interactions with the Scottish healthcare system and deaths. The number of total available records varies across sex, age, and SIMD (Figure 1B), and when records are grouped by database (Supplementary Figure S1A). In particular, marginally more records are available for individuals in the most deprived areas (as measured by deciles of the 2016 Scottish Index of Multiple Deprivation (SIMD); [Scottish Government, 2016]), particularly within accidents and emergency and mental health hospital records. Two additional tables (see Supplementary Table S2) containing historic data about long term conditions (LTC, back to 1981) and mortality records were also used as input.

We selected three time cutoffs for model fitting (1 May and 1 December 2016, and 1 May 2017) leading to 17.4 million individual-time pairs, hereafter referred to as samples (Figure 1C). This choice was informed by the extent of data required to define the input features used by the score (3 years prior the time cutoff) and the prediction target (1 year after the time cutoff). We used the earliest (1 May 2016) and latest (1 May 2017) possible time cutoffs, and a third time cutoff halfway between these. Although we could have used more than one time cutoff between the earliest and latest, we deemed that this would add little because, for most patients, we expect to have negiblible variation in their input features and EA status from month to month. After exclusions (which were predominantly due to samples without SPARRA v3 scores; see Methods), the data comprise 12.8 million samples corresponding to 4.8 million individuals. Overall, the study cohort is slightly older, has more females, and is moderately more deprived than the general population (Table 1). The prediction target was defined as a recorded EA to a Scottish hospital or death in the year following the time cutoff (see Methods). In total, 1,142,169 EA or death events (9%) were observed across all samples. This includes 57,183 samples for which a death was recorded (without a prior EA within that year) and 1,084,986 samples for which an EA was recorded (amongst those, 107,827 deaths were observed after the EA). As expected, the proportion of deaths amongst the observed events increases with age (Supplementary Figure S1B). Moreover, patients with an EA or death event (in at least one time cutoff) are, on average, older and more deprived than those without an event (Table 1).

Overall predictive performance

In held out test data, SPARRAv4 was effective at predicting EA, and outperformed SPARRAv3 on the basis of area-under-receiver-operator-characteristic (AUROC) and area-under-precision-recall-curve (AUPRC) (Figure 2A-B). SPARRAv4 was also better calibrated, particularly for samples with observed risk ≈ 0.5 (Figure 2C). Whilst SPARRAv3 and SPARRAv4 scores

Variable	Scottish population	Input data	Cohort After exclusions	EA or death	No EA or death
Sex (%)					-
Male	48.5	48.2	45.4	46.2	45.3
Female	51.5	51.8	54.6	53.7	54.7
Age at time cutoff (%)					
0-19	16.9	21.1	19.6	11.8	20.4
20-70	71.2	64.2	64.9	50.1	66.4
71+	11.9	14.7	15.4	38.1	13.2
SIMD decile (%)					
1-5	50.0	50.8	52.0	59.5	51.2
6-10	50.0	49.2	48.0	40.5	48.8
Any LTC (%)	Unknown	29.4	32.1	58.8	29.5

Table 1: **Demographic summary for the different cohorts**: the whole Scottish population (approximately 5.8 million), those present in the input databases at least one (17,488,596 samples comprising 5,829,532 unique individuals), our study cohort after exclusions (12,866,084 samples comprising 4,835,428 unique individuals) and our study cohort after stratifying by event status (EA or death: 1,142,169 samples comprising 667,566 unique individuals; no EA or death: 11,723,915 samples comprising 4,670,756 unique individuals). Summary statistics were calculated using sample-level data. The EA or death cohort includes individual-time pairs for which the individual at least one EA or died during the year after the time. LTC denotes long-term conditions (e.g. epilepsy). Data for the Scottish population is from the 2011 Census [Office for National Statistics et al., 2011].

were highly correlated, large discrepancies were observed for some samples (Supplementary Figure S2). In samples for whom v3 and v4 disagreed (defined as |v3 - v4| > 0.1), we found that v4 was better-calibrated than v3 (Figure 2D).

We also assessed the potential population-wide benefit of SPARRAv4 over SPARRAv3 directly. Amongst the 50,000 individuals judged to be at highest risk by SPARRAv3, around 4,000 fewer individuals were eventually admitted that were amongst the 50,000 individuals judged to be at highest risk by SPARRAv4 (Figure 2E). For another perspective, if we simply assume that 20% of admissions are avoidable [value taken from Blunt, 2013], that avoidable admissions are as predictable as non-avoidable admissions, and that we wish to pre-empt 3,000 avoidable admissions by targeted intervention on the highest risk patients (the second assumption is conservative, since avoidable admissions are often predictable due to other medical problems). Then, by using SPARRAv4, we would need to intervene on approximately 1,500 fewer patients than if we were to use SPARRAv3 in the same way, in order to achieve the target of avoiding 3,000 admissions (Figure 2F).

SPARRAv4 comprises an ensemble of models (see Methods), so we also explored a breakdown of AUROC/AUPRC (Table 2) and calibration (Supplementary Figure S3) across constituent models. The ensemble had slightly better performance than the best constituent models (XGB and RF). Note that some constituent models (ANN, GLM, NB) had ensemble coefficients which were regularised to be vanishingly small, so in practice scores for those models need not be computed when calculating SPARRAv4. We investigated whether performance could be improved by using separate sets of coefficients for each SPARRAv3 cohort, but found that the improvement was so small that we judged this to be unnecessary (Supplementary Note S3).

Stratified performance of SPARRAv3 and SPARRAv4

To examine differences in performance more closely, we explored the performance of SPARRAv3 and SPARRAv4 across different patient subcohorts defined by age, SIMD deciles and the four subcohorts defined as part of SPARRAv3 development. Generally, we observed that SPARRAv4 had better discrimination performance across all subcohorts (Figure 3A).

Conditional performance of SPARRAv4 by admission type and imminence

Figure 3B displays the distribution of SPARRAv4 scores stratified according to event status and, for those with an EA, according to the diagnosis that was assigned to the patient during admission (Supplementary Table S5). When comparing samples with and without an event (defined by the composite EA or death outcome), we observed the former had generally lower SPARRAv4 scores. Amongst those with an event, all-cause mortality was associated with high SPARRAv4 scores. If the event was an EA, we found that samples with certain medical classes of admission tended to have particularly high SPARRA scores, suggesting that such admissions can be predicted disproportionately well (Figure 3B): in particular, those with mental/behavioural, respiratory and endocrine/metabolic related admissions. As one would expect, we were less able to predict external causes of admissions (e.g., S21: open wound of thorax [World Health Organization, 2004]). Obstetric and puerperium-related admissions were particularly challenging to predict by SPARRAv4. Similarly, all cause mortality was also associated with high SPARRAv4 scores. As one would expect, we were less able to predict external causes of admissions (e.g., S21: open wound of thorax [World

Health Organization, 2004]). Obstetric and puerperium-related admissions were particularly challenging to predict by SPARRAv4. When further analysing SPARRAv4 scores, we also found that among individuals who had an EA during the 1 year outcome period, those with higher risk scores were likelier to have the first EA near the start of the period (Figure 3C). We did not use an absolute threshold to determine who is at high risk. Instead, we ranked individuals according to their scores and looked at those in the top part of the ranking (i.e. with the highest risk scores).

Deployment scenario stability and performance attenuation

We next addressed two crucial aspects pertaining to practical usage of SPARRAv4. Firstly, we assess the durability of performance for a model trained once (at the time cutoff 1 May 2014, using a one-year lookback) and employed to generate scores at future times (1 May and 1 December 2015, 1 May and 1 December 2016, 1 May 2017), confirming it does not deteriorate. This is the way in which SPARRAv4 will be deployed by PHS, generating new scores each month but without repeated model updating, akin to SPARRAv3's monthly use without update from 2013–2023. Secondly, we demonstrate that it is none-the-less necessary to update scores despite the absence of model updates, since evolving patient covariates lead to the performance attenuation of any point-in-time score.

We firstly used a static model M_0 (Methods) to predict risk at future time-points (i.e. new scores are generated as the features are updated). M_0 performed essentially equally well over time (Figure 4A-C), with no statistically significant decrease in performance (adjusted p-values > 0.05), or improved performance with time for all comparisons of AUROCs. With stability under the deployment scenario confirmed, we also explored the distribution of scores over time. In line with expectations, the quantiles of scores generated by the static model increased as the cohort grew older (Figure 4D). The mean risk scores of individuals in the highest centiles of risk at t_0 decreased over time (Figure 4E), suggesting that very high risk scores tend to be transient. The bivariate densities of time-specific scores (Figure 4F) also show lower scores to be more stable than higher scores, and that subjects 'jump' to higher scores (upper left in Figure 4F) more than they drop to lower scores (bottom right).

Finally, we examined the behaviour of static scores (computed at t_0 using M_0) to predict future event risk (note that the model is also static in this setting, though we will call it static scores for brevity). We observed that the static scores performed reasonably well even 2-3 years after t_0 , although discrimination and calibration were gradually lost (Supplementary Figure S4A-C). More generally, we observe that scores fitted and calculated at a fixed time cutoff had successively lower AUROCs for predicting EA over future periods (Supplementary Figure S4D). Although the absolute differences in AUROC over time with static scores are small, they are visibly larger than those seen between SPARRAv3 and SPARRAv4 (Figure 2A), indicating that comparisons analogous to Figure 2E,F would similarly show much larger differences. This affirms the need for updated scores in deployment, despite the static model.

Feature importance

The features with the largest mean absolute Shapley value (excluding SPARRAv3 and the features derived from the topic model) were age, the number of days since the last EA, the number of previous A&E attendances, and the number of antibacterial prescriptions (Table 3). Most features had non-linear effects (see e.g. Supplementary Figure S5A-B). For

example, the risk contribution from age was high in infancy, dropping rapidly from infancy through childhood, then remaining stable until around age 65, and rising rapidly thereafter (Figure 5A). We also found a non-linear importance of SIMD (Figure 5B) and number of previous emergency hospital admissions (Supplementary Figure S5C).

We further investigated the contribution of SIMD by comparing Shapley values between features. We computed the mean difference in contribution of SIMD to risk score between individuals in the most deprived and least deprived SIMD decile areas, and the additional years of age which would contribute an equivalent amount. This was generally around 10-40 additional years (Figure 5D). In terms of raw admission rates, disparity was further apparent: individuals aged 20 in lowest SIMD decile areas had similar admission rates to individuals aged 70 in the 3 highest SIMD decile areas (Figure 5E).

When exploring the added value (in terms of AUROC) of including the features derived using the topic model (Supplementary Table S4), we observed slightly better performance than the model without such features (p-value = 3×10^{-29} ; Supplementary Figure S5E-F). In some cases, topic features led to substantial changes in overall score: for example, a topic relating to skin disease contributed more than 2% to the SPARRAv4 score (roughly equivalent to the mean contribution to the score from age for individuals aged 75; see Figure 5A) for around 0.43% of individuals with the resultant SPARRAv4 scores better-calibrated than the SPARRAv3 scores, which did not use a topic model (Supplementary Note S1). Analogously to Figure 2E, we also computed the additional number of samples correctly identified as having an event amongst the top scores by the two models. Although the absolute difference in AUROC was small, we found that the use of topic features increased the number of EAs detected in the top 500,000 scores by around 200.

Deployment

SPARRAv4 was developed in a remote data safe haven (DSH) environment [Public Health Scotland, 2020] without access to internet or modern collaboration tools (e.g. git version control). Whilst our analysis code and a summary of model outputs (e.g. AUROC values) could be securely extracted from the DSH, this was not possible for the actual trained model due to potential leaks of sensitive patient information [Jefferson et al., 2022]. This introduced reproducibility challenges, since the model had to be retrained in a different secure environment before it was deployed by PHS. In particular, this re-development outside the DSH had two distinct phases. Firstly, the raw data transformations (to convert the original databases into a format that is suitable for ML algorithms) were reproduced from scratch from the same source data. Once the output of the transformations matched perfectly between the DSH and the external environment for all features, the topic and predictive models were re-trained. The training process could not be exactly matched due to differing compute environments, package versions and training/validation split. However, after training, the external models were validated by comparing the performance (via AUROC) and the calibration with the results obtained within the DSH.

Another practical issue that arises when developing and deploying a new version of SPARRA is due to potential performative prediction effects [Perdomo et al., 2020b]. Since SPARRAv3 is already visible to GPs (who may intervene to reduce the risk of high-risk patients), v3 can alter observed risk in training data used for v4, with v3 becoming a 'victim of its own success' [Lenert et al., 2019, Sperrin et al., 2019]. This is potentially hazardous: if some risk factor R confers high v3 scores prompting GP intervention (e.g., enhanced followup), then in the training data for v4, R may no longer apparently confer increased risk.

Should v4 replace v3, some individuals would therefore have their EA risk underestimated, potentially diverting important anticipatory care away from them. This highlights a critical problem in the theory of model updating [Liley et al., 2021], which we expand on in Supplementary Note and illustrate in Figure 6A-D. As a practical solution, during deployment, GPs could receive the maximum between v3 and v4 scores. This would avoid the potential hazard of risk underestimation, at the cost of mild loss of AUROC (Figure 6E) and score calibration (Figure 6F).

Discussion

We used routinely collected EHRs from around 5.8 million Scottish residents to develop and evaluate SPARRAv4, a risk score that quantifies 1-year EA risk based on age, deprivation (using SIMD as a geographic-based proxy) and a wide range of features derived from a patient's past medical history. SPARRAv4 constitutes a real-world use of ML, derived from population-level data and embedded in clinical settings across Scotland (Figure 1).

While the increases in AUROC and AUPRC over the previous version of SPARRA may be small (Figure 2A,B), the improvement provided by SPARRAv4 in terms of absolute benefit to population is substantial (Figure 2E,F). This arises from the use of more flexible ML methods (e.g. to capture non-linear patterns between features and EA risk) and the incorporation of features derived by a topic model which extracts more granular information (with respect to the manually curated features used by SPARRAv3) from past diagnoses and prescriptions data. The latter can be thought of as a proxy for multi-morbidity patterns, in that topic models identify patterns of diagnoses and prescriptions which commonly occur together [Kremer et al., 2022], which can be seen to occur in our data (Supplementary Table S4). The use of an ensemble of models also allows stronger models and methods to dominate the final predictor, and weaker models to be discarded.

Our analysis also provides insights into the epidemiology of EA risk, highlighting predictable patterns in terms of EA type (as defined by the recorded primary diagnosis; Figure 3B) and the imminence of EA (Figure 3C), in that those at high risk of an admission are likely to have an imminent admission rather than equally likely to have an admission over the year-long prediction period. Moreover, we studied the contribution of each feature, revealing a complex relationship between age, deprivation and EA risk (Figure 5). Note, however, that we cannot assign a causal interpretation for any reported associations. In particular, the link between SIMD and EA risk is complex; SIMD includes a 'health' constituent [Scottish Government, 2016], and individuals in more-deprived SIMD decile areas (1: most deprived; 10: least deprived) miss more primary care appointments [Ellis et al., 2017].

One important strength of SPARRAv4 is its nationwide coverage, using existing health-care databases without the need for additional bespoke data collection. This, however, prevents the use of primary care data (beyond community prescribing) as it is not currently centrally collected in Scotland. Due to privacy considerations, we were also unable to access geographic location data, precluding the study of potential differences between e.g. rural and urban areas and the use of a geographically separated test set [Wallace et al., 2014]. Limited data availability also limits a straightforward comparison of predictive performance (e.g. in terms of AUROC) with respect to similar models developed in England [Billings et al., 2006, Rahimian et al., 2018] (this is also complicated because of different model choices, e.g. [Rahimian et al., 2018] modelled time-to-event data but we used a binary 1-year EA

indicator). For example, we do not have information about marital and smoking status, blood test results and family histories; all of which were found to be predictive of EA risk by [Rahimian et al., 2018]. Our training dataset is non-representative of our raw dataset (which in turn is non-representative of the Scottish population, as per Table 1, as is typical of studies based on electronic health records [Verheij et al., 2018, Agniel et al., 2018]), but it does generally include individuals at higher EA risk.

Beyond model development and evaluation, our work also highlights broader challenges that arise in this type of translational project using EHR. In particular, as SPARRAv4 has the potential to influence patient care, we have placed high emphasis on transparency and reproducibility while ensuring compliance with data governance constraints. Providing our code in a publicly available repository will also allow us to transparently document future changes to the model (e.g. if any unwanted behaviour is identified during the early stages of deployment). SPARRAv4 also constitutes a real-world example in which potential performative effects need to be taken into account when updating an already deployed risk prediction model (Figure 6).

It is critical to emphasise that SPARRAv4 will not replace clinical judgement, nor does it direct changes to patient management made solely based on the score. Indeed, any potential interventions must be decided jointly by medical professionals and patients, balancing the underlying risks and benefits. Moreover, lowering EA risk does not necessarily entail overall patient benefit as e.g. long-term oral corticosteroid use in mild asthmatics would reduce EA risk, but the corticosteroids themselves cause an unacceptable cost of long-term morbidity [NICE guidelines, 2017].

Optimal translation into clinical action is a vital research area and is essential for quantifying the benefit of such scores in clinical practice. Indeed, any benefit is dependent on widespread uptake and the existence of timely integrated health and social care interventions, and identification of EA risk is only the first step in this pathway. As such, the evaluation of real-world effectiveness for SPARRAv4 and similar risk scores is complex, and requires a multi-disciplinary approach that considers a variety of factors (e.g. the local health economy and the capacity to deliver pre-emtive interventions in primary care) Therefore, we will continue to collaborate to achieve successful deployment of SPARRAv4 and will carefully consider the feedback from GPs to improve the model and the communication of its results further (e.g. via informative dashboards). As the COVID-19 pandemic resolves, it will also be important to assess potential effects of dataset shift [Subbaswamy and Saria, 2020 due to disproportionate mortality burden in older individuals and long-term consequences of COVID-19 infections. In an era where healthcare systems are under high stress, we hope that the availability of robust and reproducible risk scores such as SPARRAv4 (and its future developments) will contribute to the design of proactive interventions that reduce pressures on healthcare systems and improve healthy life expectancy.

Methods

SPARRAv3

SPARRAv3 [Health and Social Care Information Programme, 2011], deployed in 2012, uses separate logistic regressions on four subcohorts of individuals: frail elderly conditions (FEC; individuals aged > 75); long-term conditions (LTC; individuals aged 16-75 with prior health-care system contact), young emergency department (YED; individuals aged 16-55 who have had at least one A&E attendance in the previous year) and under-16 (U16; individuals

aged < 16). If an individual belongs to more than one of these groups, the maximum of the associated scores is reported. SPARRAv3 was fitted once (at its inception in 2012) with regression coefficients remaining fixed thereafter. Most input features were manually dichotomised into two or more ranges for fitting and prediction. The prediction target for SPARRAv3 is EA within 12 months. People who died in the pre-prediction period, and who therefore do not have an outcome for use in the analysis, are excluded. PHS calculated SPARRAv3 scores and provided them as input for the analysis described herein. Any GP in Scotland can access SPARRA scores after attaining information governance approval.

Exclusion criteria

The exclusion criteria were applied per sample (defined as individual-time pairs; Figure 1C). Samples were excluded if: (i) they were excluded from SPARRAv3 (these are individuals for which PHS did not calculate a SPARRAv3 score and largely correspond to individuals with no healthcare interactions or that were not covered by the four SPARRAv3 subcohorts; [Health and Social Care Information Programme, 2011]), (ii) when the individual died prior to the prediction time cutoff, (iii) when the SIMD for the individual was unknown, or (iv) those associated to individuals whose Community Health Index [CHI; ISD Scotland Data Dictionary, 2023] changed during the study period ('Unmatched' in Figure 1). The CHI number is a unique identifier which is used in Scotland for health care purposes. Rates of EA and death in the follow-up period were generally lower in excluded samples than in included samples (3.40% versus 8.88%, only considering exclusions which were not due to the individual having died prior to the time cutoff; Supplementary Table S6). Exclusion criteria (i) and (ii) were applied at the sample level, while exclusion criteria (iii) and (iv) were applied at the individual level.

Feature engineering

A typical entry in the source EHR tables (Supplementary Table S2) recorded a single interaction between a patient and NHS Scotland (e.g. hospitalisation), comprising a unique individual identifier (an anonymised version of the CHI number), the date on which the interaction began (admission), the date it ended (discharge), and further details (diagnoses made, procedures performed). For each sample, entries from up to three years before the time cutoff were considered when building input features, except long-term condition (LTC) records, which considered all data since recording began in January 1981. A full feature list is described in Supplementary Table S3. This includes SPARRAv3 [Health and Social Care Information Programme, 2011] features, e.g. age, sex, SIMD deciles and counts of previous admissions (e.g. A&E admissions, drug-and-alcohol-related admissions). Additional features encoding time-since-last-event (e.g. days since last outpatient attendance) were included following findings in [Rahimian et al., 2018]. From community prescribing data, we derived predictors encoding the number of prescriptions of various categories (e.g. respiratory), extending the set of predictors beyond a similar set used in SPARRAv3. Similarly to SPARRAv3, we also derived the total number of different prescription categories, the total number of filled prescription items, and the number of British National Formulary (BNF) sections from which a prescription was filled [Prasad, 1994]. From LTC records, we extracted the number of years since diagnosis of each LTC (e.g. asthma), the total number of LTCs recorded, and the number of LTCs resulting in hospital admissions.

Data from prescription records and recorded diagnoses tend to be sparse, in that most

medications and diagnoses will only be recorded for a small proportion of the population. We used our topic model [Blei et al., 2003] to assimilate this data, by jointly modelling prescriptions and diagnoses using 30 topics (effectively clusters of prescriptions and diagnoses), considering samples as 'documents' and diagnoses/prescriptions as 'words'. This enabled a substantial reduction in feature dimensionality, given the number of diagnoses/prescription factor levels. Using the map from documents to topic probabilities, we used derived topic probabilities as additional features in SPARRAv4, which corresponded to sample-wise membership of each topic.

Choice of prediction target for SPARRAv4

The primary target for SPARRA is to predict whether an individual will experience an EA within 12 months from the prediction cutoff. A problem arises due to the deaths during the follow-up year for which the target may be unknown (e.g. if someone died within 6 months, without a prior EA). Broadly, there are four options for how to treat such individuals during model training and testing:

- 1. Exclude them from the dataset
- 2. Treat them according to whether they had an emergency admission before they died
- 3. Treat them as no admission, or
- 4. Treat them as an admission

It would also be possible to code death in follow-up differentially; for instance, coding in-hospital death as EA and in-community death as exclusions or non-EA. Our choice not to code all deaths identically is in the interests of non-maleficence. If an individual is at risk of imminent death in the community they will typically be admitted to hospital if it is possible to react in time, with a possible exemption if this is not in their best interests.

Option 1 would exclude the most critically ill individuals from the dataset and hence was discarded. Option 2 would effectively mean such individuals have a follow-up time less than a year, and would classify individuals who died without a hospital admission as having had a 'desirable' outcome. Option 3 would effectively classify death as a 'desirable' outcome, so we avoided it. The consequences from coding community deaths as non-EA would be severe, as it could mean that healthier individuals at risk of sudden death are either coded as non-EA or excluded from the dataset, potentially leading to inappropriately low scores being assigned to these individuals. This could draw treatment away from individuals in high need. Instead, option 4 allows the general description of the target as 'a catastrophic breakdown in health'. In this case, our model would not be able to distinguish community deaths from emergency admissions: we may assign high 'EA' scores to the very old and terminally ill, when in fact these individuals may be treated in the community rather than admitted. The potential harm from this option is small. It could mean that such individuals are excessively treated rather than palliated, but since palliation over treatment is an active decision [Romo et al., 2017] and such individuals are generally known to be high-risk it is unlikely that the SPARRA score will adversely affect any decisions in this case. As the philosophy of the SPARRA score is to avert breakdowns in health, of which death can be considered an example, we decided to use a composite prediction target (EA or death within 12 months) which is consistent with option 4.

Machine learning prediction methods

For SPARRAv4, we had no prior belief that any ML model class would be best, so considered a range of binary prediction approaches (hereafter referred to as constituent models). The following models were fitted using the h2o [LeDell et al., 2019] R package (version 3.24.0.2): an artificial neural network (ANN), two random forests (RF) (depth 20 and 40), an elastic net generalised linear model (GLM) and a naive Bayes (NB) classifier. The xgboost [Chen et al., 2019] R package (version 1.6.0.1) was used to train three gradient-boosted trees (XGB) models (maximum tree depth 3, 4, and 8). Hyper-parameter choices are described in Methods. SPARRAv3 was used as an extra constituent model.

Rather than selecting a single constituent model, we used an ensemble approach. Similar to [Van der Laan et al., 2007], we calculated an optimal linear combination (L_1 -penalised regression, using the R package glmnet, version 4.1.4) of the scores generated by each constituent model. Ensemble weights were chosen to optimise the AUROC. Finally, we monotonically transformed the derived predictor to improve calibration by inverting the empirical calibration function (Supplementary Note S2).

Data imputation

As all non-primary care interactions with NHS Scotland are recorded in the input databases, there was no missingness for most features. For 'time-since-interaction' type features, samples for which there was no recorded interaction were coded as twice the maximum lookback time. There was minor non-random missingness in topic features (\sim 0.8%) due to individuals in the dataset with no diagnoses or filled prescriptions, for whom topic probabilities could not be calculated. We used mean-value imputation in the ANN and GLM models (deriving mean values from training data only), used missingness to inform tree splits (defaults in [LeDell et al., 2019]) in RF, used sample-wise imputation in XGB (as per [Chen et al., 2019]) and dropped during fitting (default in [LeDell et al., 2019]) in NB (omitted missing values for prediction). All imputation rules were determined using training sets only.

Particular care was required for features encoding total lengths of hospital stays. In some cases, a discharge date was not recorded, which could lead to an erroneous assumption of a very long hospital stay (from admission until the time cutoff). To address this, we truncated apparently spuriously long stays at data-informed values (Supplementary Note S4).

Hyperparameter choice for ML prediction methods

We used a range of constituent models. The h2o [LeDell et al., 2019] R package (version 3.24.0.2) was used to train ANN, RF, GLM and NB models. The xgboost [Chen et al., 2019] R package (version 1.6.0.1) was used to train the XGB models. Unless otherwise specified, hyperparameters were set as the software defaults. When tuned, hyperparameter values were chosen to optimise the default objective functions implemented for each method: logloss or the ANN, RFs and GLM, likelihood for the NB model; and a logistic objective for the XGB trees. In all cases, hyperparameters were determined by randomly splitting the relevant dataset into a training and test set of 80% and 20% of the data respectively. Details for each method are provided below. Only limited hyperparameter tuning was possible due to the restricted computational environment in the data safe haven (see Results)

SPARRAv3

SPARRAv3 scores were calculated by PHS using their existing algorithm Health and Social Care Information Programme [2011].

Artificial neural network (ANN)

We used a training dropout rate of 20% to reduce generalisation error. We optimised over the number of layers (1 or 2) and the number of nodes in each layer (128 or 256).

Random forest (RF)

We fitted two RF: one had maximum depth 20 and 500 trees, and the other had maximum depth 40 and 50 trees (both taking a similar time to fit).

Gradient-boosted trees (XGB)

We fitted three boosted tree models with three maximum depths: 3, 4, and 8. For the deeper-tree model, we set a low step size shrinkage $\eta = 0.075$ and a positive minimum loss reduction $\gamma = 5$ in order to avoid overfitting. In the other two models, we used default values of $\eta = 0.3$, $\gamma = 0$.

Naive Bayes (NB)

The only hyperparameter we tuned was a Laplace smoothing parameter, varying between 0 and 4.

Penalised Generalised linear model (GLM)

We optimised L_1 and L_2 penalties (an elastic net), considering total penalty $(L_1 + L_2)$ in $10^{-\{1,2,3,4,5\}}$, and a ratio L_1/L_2 in $\{0,0.5,1\}$.

Cross-validation

We fitted and evaluated SPARRAv4 using three-fold cross-validation (CV). We considered three-fold cross validation acceptable in our case given the size of our dataset [Bates et al., 2023]. This was designed such that all elements of the model evaluated on a test set were agnostic to samples in that test set. Individuals were randomly partitioned into three data folds (F1, F2 and F3). At each CV iteration, F1 and F2 were combined and used as a training dataset, F3 was used as a test dataset. The training dataset (F1+F2) was used to fit the topic model and to train all constituent models (except SPARRAv3, whose training anyhow pre-dates the data used here). The ensemble weights and re-calibration transformation were learned using F1 + F2, i.e. without using the test set from the test set (Supplementary Note S2).

Predictive performance

Our primary endpoint for model performance was AUROC. We also considered area-underprecision-recall curves (PRC) and calibration curves. We plotted calibration curves using a kernelised calibration estimator (Supplementary Note S5). For simplicity, figures show ROC/PRC that were calculated by combining all samples from the three *test* CV folds (that is, all scores and observed outcomes were merged to draw a single curve). Quoted AUROC/AUPRC values were calculated as an average across the three *test* CV folds to avert problems from between-fold differences in models [Forman and Scholz, 2010]. For ease of comparison, we also used mean-over-folds to compute quoted AUROCs and AUPRCs for SPARRAv3, although the latter was not fitted to our data.

Deployment scenario stability and performance attenuation

Using the same analysis pipeline as for the development of SPARRAv4, we trained a static model M_0 to an early time cutoff (t_0 =1 May 2014), and using one year of data prior to t_0 to derive predictors (the restricted lookback is the only deviation from the actual model pipeline, due to limited temporal span of the training data).

We studied the performance of M_0 as a static model to repeatedly predict risk at future time cutoffs, which mirrors the way in which PHS will deploy the model. To do this, we assembled test features from data 1 year prior to t_1 =1 May 2015, t_2 =1 Dec 2015, t_3 =1 May 2016, t_4 =1 Dec 2016, and t_5 =1 May 2017, applying M_0 to predict EA risk in the year following each time-point. In this analysis, the comparison of the distribution of scores over time only considered the cohort of patients who were alive and had valid scores at t_1, \ldots, t_5 .

To ensure a fair comparison when evaluating the performance of *static scores* (computed at t_0 using M_0) to predict future event risk (at t_1, \ldots, t_5), we only considered a subsample of 1 million individuals with full data across all time-points, selected such that global admission rates matched those at t_0 .

Assessment of feature importance

We examined the contribution of feature to risk scores at an individual level by estimating Shapley values [Lundberg and Lee, 2017] for each feature. For simplicity, this calculation was done using 20,000 randomly-chosen samples in the first cross-validation fold (F1). We treated SPARRAv3 scores as fixed predictors rather than as functions of other predictors.

We also assessed the added value of inclusion of topic-model derived features, which summarise more granular information about the previous medical history of a patient with respect to those included in SPARRAv3. For this purpose, we refitted the model to F2+F3 with topic-derived features excluded from the predictor matrix. We compared the performance of these models using F1 as test data. We compared the performance of predictive models with and without the features derived from the topic model by comparing AUROC values using DeLong's test [DeLong et al., 1988].




Figure 1: **Data and model fitting overview.** (A) Illustration of how SPARRA can support primary care intervention with the goal of improving patient outcomes. (B) Distribution of the number of input EHR entries (prior to exclusions) according to age, sex and SIMD deciles (1: most deprived; 10: least deprived). (C) Flow chart summarising data and model fitting pipelines.




Figure 2: Comparison of overall predictive performance between SPARRAv3 and SPARRAv4. (A) ROC. (B) PRC. Lower sub-panels show differences in sensitivity and precision, respectively. Confidence intervals are negligible. (C) Calibration curves. (D) Calibration curves for samples in which |v4-v3|>0.1. Lower sub-panels show the difference between curves and the y=x line (perfect calibration). Confidence envelopes are pointwise (that is, for each x-value, not the whole curve). Predicted/true value pairs are combined across cross-validation folds in all panels for simplicity. (E) Difference in the number of individuals who had an event amongst individuals designated highest-risk by v3 and v4. The repeating pattern is a rounding effect of v3. (F) Difference in the number of highest-risk individuals to target to avoid a given number of admissions.

Model	AUROC	Fold 1 AUPRC	Coef.
ANN	0.7613	0.346	0
Penalised GLM	0.7879	0.3657	0
Naive Bayes	0.7471	0.2233	0
RF, depth: 20	0.7927	0.3787	0.3624
RF, depth: 40	0.7845	0.3666	0
SPARRAv3	0.7812	0.3568	0
XGB depth: 4	0.7981	0.3839	0.6626
XGB depth: 8	0.7984	0.3873	2.004
XGB depth 3	0.7984	0.3864	1.363
Ensemble	0.7989	0.3888	

Model		Fold 2	
Model	AUROC	AUPRC	Coef.
ANN	0.7698	0.3479	0
Penalised GLM	0.7874	0.367	0
Naive Bayes	0.7468	0.2238	0
RF, depth: 20	0.7928	0.3799	0.3749
RF, depth: 40	0.7844	0.3678	0
SPARRAv3	0.7809	0.3584	0
XGB depth: 4	0.7975	0.3839	0.6579
XGB depth: 8	0.798	0.3881	1.162
XGB depth 3	0.7981	0.387	1.727
Ensemble	0.7987	0.3895	

Model	Fold 3		Mean over folds		
Model	AUROC	AUPRC	Coef.	AUROC	AUPRC
ANN	0.7693	0.3525	0	0.7668	0.3488
Penalised GLM	0.7878	0.3661	0	0.7877	0.3663
Naive Bayes	0.7468	0.2246	0	0.7469	0.2239
RF, depth: 20	0.7926	0.3791	0.5013	0.7927	0.3792
RF, depth: 40	0.784	0.3674	0	0.7843	0.3672
SPARRAv3	0.7809	0.3572	0	0.7810	0.3574
XGB depth: 4	0.7973	0.3837	0.9105	0.7976	0.3838
XGB depth: 8	0.7978	0.3877	1.116	0.7981	0.3877
XGB depth 3	0.798	0.3867	1.418	0.7982	0.3867
Ensemble	0.7985	0.3891		0.7987	0.3891

Table 2: Overall discrimination performance for SPARRAv4 and its constituent models. Areas under ROC curves and PR curves by fold for each constituent predictor and ensemble. Columns 'Coef.' indicate estimated coefficients (weights) in the final ensemble (see Methods section for details). All standard errors for AUROCs are $< 5 \times 10^{-4}$ and for AUPRCs are $< 8 \times 10^{-4}$




Figure 3: Stratified performance of SPARRAv3 and SPARRAv4. (A) Performance of SPARRAv3 and SPARRAv4 in subcohorts defined by age, SIMD and the original subcohorts defined during SPARRAv3 development (Methods). Top: AUROC (blue: SPARRAv3; red: SPARRAv4). Vertical bars denote plus/minus 3 standard deviations. Middle: AUROC increase for SPARRAv4 with respect to SPARRAv3. For context, bottom sub-panels show the proportion of samples with an event within each group. (B) Distribution of SPARRAv4 scores (in log-scale) based on the type of diagnosis recorded during the admission (see Supplementary Table S5 for definitions). Black points indicate the associated medians. Groups were defined according to whether an event was observed (grey violin plots) or, for those with an EA, based on the diagnosis recorded during the admission (black violin plots). (C) Density of time-to-first-EA (that is, days between time cutoff and first EA date) in subsets of individuals who had an EA in the year following the time cutoff and had a SPARRAv4 score above a given cutoff. For instance, the lightest line shows density of time-to-first-EA in samples who had an EA and had SPARRAv4¿0.8




Figure 4: **Performance of a static model with changing scores over time.** (A-C) Performance of scores calculated at $t_1 - t_5$ from static model M_0 . (A) ROC curves. Lower panel shows differences in sensitivity with respect to t_1 . (B) PRC curves. Lower panel shows differences in precision with respect to t_1 . (C) Calibration curves. Lower panel shows the difference between observed and expected EA frequency. (D) Centiles (grey) and deciles (black) of risk scores (calculated using M_0) over time, across all individuals with data available at all time cutoffs. (E) Average score over time for groups of individuals defined by risk centiles (grey) and deciles (black) at time t_0 (2 May 2015). (F) Density (low to high: white-grey-red-yellow) of scores generated using the static model M_0 to predict EA risk at t_1 (2 May 2015) and t_2 (1 Dec 2015). The density is normalised to uniform marginal on the Y axis, then the X axis; true marginal distributions of risk scores are shown alongside in grey.




Figure 5: **Analysis of Shapley values.** Distribution of Shapley values by (A) age and (B) SIMD deciles (1: most deprived; 10: least deprived). (C) Number of additional years of age needed to match the difference in Shapley values between SIMD deciles 1 and 10. (D) 'Effective ages' calculated to match EA rates: for an (age, SIMD decile) pair, the age at mean SIMD with the equivalent EA rate.

Variable	Importance
Age at time cutoff	1.530
Days since last emergency admission	0.752
Number of previous A&E attendances	0.509
Number of antibacterial prescriptions	0.376
Number of central nervous system related prescriptions	0.375
Male sex	0.373
Days since last A&E attendance	0.321
SIMD decile	0.310
Number of emergency bed days	0.299
Days since last acute admission of any type	0.285
Days since last outpatient attendance	0.257
Number of diuretic prescriptions	0.213
Number of lipid lowering drug prescriptions	0.194
Number of previous first outpatient appointments	0.190
Number of recorded long term conditions	0.173
Number of emergency admissions	0.161
Total number of filled prescriptions	0.160
Number of antianaemic prescriptions	0.159
Number of bronchodilator prescriptions	0.152
Number of BNF sections from which a prescription was filled	0.141

Table 3: Top 20 most important variables by mean absolute Shapley value (percentage scale). Importance can be interpreted as the average percent added or subtracted to risk score due to this factor.




Figure 6: Model updating in the presence of performative effects. (A-D) Causal structure for the training and deployment of SPARRAv3 and SPARRAv4. X_i represents covariates for a patient-time pair; v3(fit)/v4(fit) and $v3(X_i)/v3(X_i)$ represent the fitting and deployment of v3 and v4 respectively. (A) Training setting for SPARRAv3. (B) Training setting for SPARRAv4. (C) Deployment setting if SPARRAv4 were to naively replace SPARRAv3. (D) Deployment setting in which SPARRAv4 is used as an adjuvant to SPARRAv3. (E) Comparison of discrimination (ROC) between SPARRAv4 and the maximum of both scores. (F) Comparison of calibration between SPARRAv4 and the maximum of both scores.

Model updating in the presence of performative effects

We aim to produce the SPARRA score to accurately estimate EA risk over a year under normal medical care. In other words, the score should represent the EA risk if GPs do not already have access to such a risk score. Because GPs see a SPARRA score (SPARRAv3) and may act on it, the observed risk may be lower than predicted - the score may become a 'victim of its own success' [Lenert et al., 2019, Sperrin et al., 2019] due to performative effects Perdomo et al. [2020a]. Unfortunately, since the SPARRAv3 score is widely available to Scottish GPs, and may be freely acted on, we cannot assess the behaviour of the medical system in its absence. This is potentially hazardous [Liley et al., 2021].

Formally, at a given fixed time, for each individual, the value of 'EA in the next 12 months' is a Bernoulli random variable. The probability of the event for individual i is conditional on a set of covariates X_i derived from their EHR. We denote $v3(X_i)$, $v4(X_i)$ the derived SPARRAv3 and SPARRAv4 scores as functions of covariates, and assume a causal structure shown in Figure 6 (for simplicity, we assume there are no unobserved confounders but the same argument applies in their presence). With no SPARRA-like predictive score in place, there is only one causal pathway $X_i \to EA$. It is to this system (coloured red) that v3 was fitted. Here, $v3(X_i)$ estimates the 'native' risk $Pr(EA|X_i)$ (ignoring previous versions of the SPARRA score, which covered < 30% of the population). Although $v3(X_i)$ is determined entirely by X_i , the act of distributing values of $v3(X_i)$ to GPs opens a second causal pathway from X_i to EA (Figure 6) driven by GP interventions made in response to $v3(X_i)$ scores. It is to this system (coloured red) that SPARRAv4 is fitted. Hence, $v4(X_i)$ is an estimator of $Pr(EA|X_i, v3(X_i))$, a 'conditional' risk after interventions driven by $v3(X_i)$ have been implemented.

If SPARRAv4 naively replaced SPARRAv3 (Figure 6), we would be using $v4(X_i)$ to predict behaviour of a system different to that on which it was trained (Figure 6). To amend this problem, we propose to use SPARRAv4 in *conjunction* with SPARRAv3 rather than to completely replace it (Figure 6). Ideally, GPs would be given $v3(X_i)$ and $v4(X_i)$ simultaneously and asked to *firstly* observe and act on $v3(X_i)$, then observe and act on $v4(X_i)$, thereby only using $v4(X_i)$ as per Figure 6. This is impractical, so instead, we propose to distribute a single value (given by the maximum between $v3(X_i)$ and $v4(X_i)$), avoiding the potential hazard of risk underestimation, at the cost of mild loss of score calibration (Figure 6).

Supporting information

Supplementary Table S1 Checklist for TRIPOD guidelines [Collins et al., 2015].

Supplementary Table S2 Definition of input features for SPARRAv4

Supplementary Table S3 Definition of input features for SPARRAv4.

Supplementary Table S4 Exploration of contributors to each topic.

Supplementary Table S5 Definition of different admission types.

 ${\bf Supplementary\ Table\ S6} \quad {\bf Frequency\ of\ admissions\ and\ deaths\ amongst\ excluded\ samples.}$

Supplementary Table S7 Coefficients of ensemble when fitted separately to SPARRAv3 cohorts.

Supplementary Figure S1 Extended data overview.

Supplementary Figure S2 Density plot comparing SPARRAv3 and SPARRAv4 scores.

Supplementary Figure S3 Calibration curves for SPARRAv4 model constituents.

Supplementary Figure S4 Performance of a static model and static scores used to predict risk at future time cutoffs.

Supplementary Figure S5 Feature importance

Supplementary Note S1 Analysis of specific effects of a topic feature.

Supplementary Note S2 Details of the re-calibration procedure.

Supplementary Note S3 Investigation of use of SPARRAv3-cohort specific ensemble coefficients

Supplementary Note S4 Imputation of lengths of stay when discharge date was missing.

Supplementary Note S5 Assessment of calibration.

Code and data sharing

Raw data for this project are patient-level EHR, and are confidential. Due to the confidential nature of the data, all analysis took place on a remote "data safe haven", without access to internet, software updates or unpublished software. Information Governance training was required for all researchers accessing the analysis environment. Moreover, to avoid the risk of accidental disclosure of sensitive information, an independent team carried out statistical disclosure control checks on all data exports, including the outputs presented in this manuscript. All analysis code and co-ordinates required to reproduce our Figures are available in github.com/jamesliley/SPARRAv4. This manuscript conforms to the TRIPOD guidelines [Collins et al., 2015] (Supplementary Table S1).

Ethics statement

The project was covered under National Safe Haven Generic Ethical Approval (favourable ethical opinion from the East of Scotland NHS Research Ethics Service).

Acknowledgements

The authors note that this project's success was entirely contingent on close co-operation between the Alan Turing Institute and PHS. We thank all individuals involved in primary care in Scotland for the continued support of the SPARRA project and the Public Benefit and Privacy Panel for Health and Social Care (study number 1718-0370) for Information Governance approval on behalf of the Health Boards in NHS Scotland.

All author contributions were significant and essential to the completion of this work. Author contributions were as follows: Manuscript preparation: JL, SRE, BAM, SJV, CAV, LJMA, IT; Project initiation: SJV, CAV, LJMA, CH; Model design: JL, GB, SJV, CAV, LJMA; Code and scripts: JL, GB, LJMA; NC; IT; SDR; Code review and checking: SRE, IT; SDR; Setup of computational system: GB, LJMA; Data access management: DC, RP; EHR access: KB, DC, JI, RP, SO, SR; Public health input: KB, DC, SO, JI, RP, SR; Medical input: JL, BAM, KM; Core planning group: JL, GB, SRE, BAM, KB, DC, JI, KM, RP, SJV, CAV, LJMA; Logistical and legal oversight of project: SH, KP.

Computing for this project was performed in the Scottish National Safe Haven (NSH), which is commissioned by eDRIS, Public Health Scotland from EPCC, based at The University of Edinburgh. The authors would like to acknowledge the support of the eDRIS Team for their involvement in obtaining approvals, provisioning and linking data and the use of the secure analytical platform within the National Safe Haven.

We thank the Alan Turing Institute, PHS, the MRC Human Genetics Unit at the University of Edinburgh, Durham University, University of Warwick, Wellcome Trust, Health Data Research UK, and King's College Hospital, London for their continuous support of the authors. JL, IT, CAV and LJMA were partially supported by Wave 1 of The UKRI Strategic Priorities Fund under the EPSRC Grant EP/T001569/1, particularly the "Health" theme within that grant and The Alan Turing Institute; JL, IT, BAM, CAV, LJMA and SJV were partially supported by Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England), the devolved administrations, and leading medical research charities; SJV, NC and GB were partially supported by the University of Warwick Impact Fund. SRE is funded by the EPSRC doctoral

training partnership (DTP) at Durham University, grant reference EP/R513039/1; LJMA was partially supported by a Health Programme Fellowship at The Alan Turing Institute; CAV was supported by a Chancellor's Fellowship provided by the University of Edinburgh. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Conflicts of interest

The authors declare no conflicts of interest.

References

- Denis Agniel, Isaac S Kohane, and Griffin M Weber. Biases in electronic health record data due to processes within the healthcare system: retrospective observational study. *Bmj*, 361, 2018.
- N Bajaj, S Jauhar, and J Taylor. Scottish patients at risk of readmission and admissionmental health (SPARRA MH) case study of users and non-users of a national information source. *Health Syst Policy Res*, 3:3, 2016.
- Stephen Bates, Trevor Hastie, and Robert Tibshirani. Cross-validation: what does it estimate and how well does it do it? *Journal of the American Statistical Association*, pages 1–12, 2023.
- John Billings, Jennifer Dixon, Tod Mijanovich, and David Wennberg. Case finding for patients at risk of readmission to hospital: development of algorithm to identify high risk patients. *BMJ*, 333(7563):327, 2006.
- David M Blei, Andrew Y Ng, and Michael I Jordan. Latent Dirichlet allocation. *Journal of machine Learning research*, 3(Jan):993–1022, 2003.
- Ian Blunt. Focus on preventable admissions. London: Nuffield Trust, 2013.
- Alex Bottle, Paul Aylin, and Azeem Majeed. Identifying patients at high risk of emergency hospital admissions: a logistic regression analysis. *Journal of the Royal Society of Medicine*, 99(8):406–414, 2006.
- Anne Canny, Frances Robertson, Peter Knight, Adam Redpath, and Miles D Witham. An evaluation of the psychometric properties of the indicator of relative need (IoRN) instrument. *BMC geriatrics*, 16(1):1–10, 2016.
- Tianqi Chen, Tong He, Michael Benesty, Vadim Khotilovich, Yuan Tang, Hyunsu Cho, Kailong Chen, Rory Mitchell, Ignacio Cano, Tianyi Zhou, Mu Li, Junyuan Xie, Min Lin, Yifeng Geng, and Yutian Li. xgboost: Extreme Gradient Boosting, 2019. URL https://CRAN.R-project.org/package=xgboost. R package version 0.90.0.2.
- Joanna Coast, Abby Inglis, and Stephen Frankel. Alternatives to hospital care: what are they and who should decide? *BMJ*, 312(7024):162–166, 1996.
- Gary S Collins, Johannes B Reitsma, Douglas G Altman, and Karel GM Moons. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): the tripod statement. *Journal of British Surgery*, 102(3):148–158, 2015.
- Elizabeth R DeLong, David M DeLong, and Daniel L Clarke-Pearson. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*, pages 837–845, 1988.
- David A Ellis, Ross McQueenie, Alex McConnachie, Philip Wilson, and Andrea E Williamson. Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis. *The Lancet Public Health*, 2(12): e551–e559, 2017.

- George Forman and Martin Scholz. Apples-to-apples in cross-validation studies: pitfalls in classifier performance measurement. *Acm Sigkdd Explorations Newsletter*, 12(1):49–57, 2010.
- Health and Social Care Information Programme. A report on the development of SPARRA version 3 (developing risk prediction to support preventative and anticipatory care in Scotland), 2011. https://www.isdscotland.org/Health-Topics/Health-and-Social-Community-Care/SPARRA/2012-02-09-SPARRA-Version-3.pdf, Accessed: 6-3-2020.
- Gill Highet, Debbie Crawford, Scott A Murray, and Kirsty Boyd. Development and evaluation of the supportive and palliative care indicators tool (SPICT): a mixed-methods study. *BMJ supportive & palliative care*, 4(3):285–290, 2014.
- Julia Hippisley-Cox and Carol Coupland. Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score. *BMJ open*, 3 (8):e003482, 2013.
- ISD Scotland Data Dictionary. CHI Community Health Index, 2023. https://www.ndc.scot.nhs.uk/Dictionary-A-Z/Definitions/index.asp?ID=128, Accessed: 17-3-2023.
- Emily Jefferson, James Liley, Maeve Malone, Smarti Reel, Alba Crespi-Boixader, Xaroula Kerasidou, Francesco Tava, Andrew McCarthy, Richard Preen, Alberto Blanco-Justicia, et al. GRAIMATTER green paper: Recommendations for disclosure control of trained machine learning (ML) models from trusted research environments (TREs). arXiv preprint arXiv:2211.01656, 2022.
- Ron Kremer, Syed Mohib Raza, Fabiola Eto, John Casement, Christian Atallah, Sarah Finer, Dennis Lendrem, Michael Barnes, Nick J Reynolds, and Paolo Missier. Tracking trajectories of multiple long-term conditions using dynamic patient-cluster associations. In 2022 IEEE International Conference on Big Data (Big Data), pages 4390–4399. IEEE, 2022.
- Attakrit Leckcivilize, Paul McNamee, Christopher Cooper, and Robby Steel. Impact of an anticipatory care planning intervention on unscheduled acute hospital care using difference-in-difference analysis. *BMJ health & care informatics*, 28(1), 2021.
- Erin LeDell, Navdeep Gill, Spencer Aiello, Anqi Fu, Arno Candel, Cliff Click, Tom Kraljevic, Tomas Nykodym, Patrick Aboyoun, Michal Kurka, and Michal Malohlava. h2o: R Interface for 'H2O', 2019. URL https://CRAN.R-project.org/package=h2o. R package version 3.26.0.2.
- Matthew C Lenert, Michael E Matheny, and Colin G Walsh. Prognostic models will be victims of their own success, unless.... Journal of the American Medical Informatics Association, 26(12):1645–1650, 2019.
- James Liley, Samuel R Emerson, Bilal A Mateen, Catalina A Vallejos, Louis JM Aslett, and Sebastian J Vollmer. Model updating after interventions paradoxically introduces bias. AISTATS proceedings, 2021.
- Scott M Lundberg and Su-In Lee. A unified approach to interpreting model predictions. In *Advances in neural information processing systems*, pages 4765–4774, 2017.

- David Lyon, Gillian A Lancaster, Steve Taylor, Chris Dowrick, and Hannah Chellaswamy. Predicting the likelihood of emergency admission to hospital of older people: development and validation of the emergency admission risk likelihood index (EARLI). Family practice, 24(2):158–167, 2007.
- S Manoukian, S Stewart, N Graves, H Mason, C Robertson, S Kennedy, J Pan, L Haahr, SJ Dancer, B Cook, et al. Evaluating the post-discharge cost of healthcare-associated infection in NHS Scotland. *Journal of Hospital Infection*, 114:51–58, 2021.
- Matthew BA McDermott, Shirly Wang, Nikki Marinsek, Rajesh Ranganath, Luca Foschini, and Marzyeh Ghassemi. Reproducibility in machine learning for health research: Still a ways to go. *Science Translational Medicine*, 13(586):eabb1655, 2021.
- Marian S McDonagh, David H Smith, and Maria Goddard. Measuring appropriate use of acute beds: a systematic review of methods and results. *Health policy*, 53(3):157–184, 2000.
- NICE guidelines. Asthma: diagnosis, monitoring and chronic asthma management. *National Institute of Health and Care Excellence*, November 2017.
- Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency. 2011 census aggregate data. UK data service (edition: June 2011), 2011.
- Juan Perdomo, Tijana Zrnic, Celestine Mendler-Dünner, and Moritz Hardt. Performative prediction. In *International Conference on Machine Learning*, pages 7599–7609. PMLR, 2020a.
- Juan Perdomo, Tijana Zrnic, Celestine Mendler-Dünner, and Moritz Hardt. Performative prediction. In *International Conference on Machine Learning*, pages 7599–7609. PMLR, 2020b.
- Anne B Prasad. British National Formulary. Psychiatric Bulletin, 18(5):304–304, 1994.
- Public Health Scotland. eDRIS Products and Services, Public Health Scotland, 2020. URL https://www.isdscotland.org/Products-and-Services/eDRIS/.
- Public Health Scotland. Acute hospital activity and NHS beds information for Scotland, 2022. URL https://publichealthscotland.scot/media/15288/2022-09-27-annual-acuteactivity-report.pdf.
- Fatemeh Rahimian, Gholamreza Salimi-Khorshidi, Amir H Payberah, Jenny Tran, Roberto Ayala Solares, Francesca Raimondi, Milad Nazarzadeh, Dexter Canoy, and Kazem Rahimi. Predicting the risk of emergency admission with machine learning: Development and validation using linked electronic health records. *PLoS medicine*, 15(11): e1002695, 2018.
- Rafael D Romo, Theresa A Allison, Alexander K Smith, and Margaret I Wallhagen. Sense of control in end-of-life decision-making. *Journal of the American Geriatrics Society*, 65 (3):e70-e75, 2017.
- Rural Access Action Team. The national framework for service change in NHS Scotland. Scottish Executive, Edinburgh, 2005.

- Colin Sanderson and Jennifer Dixon. Conditions for which onset or hospital admission is potentially preventable by timely and effective ambulatory care. *Journal of health services research & policy*, 5(4):222–230, 2000.
- Scottish Government. Scottish index of multiple deprivation, 2016.
- Matthew Sperrin, David Jenkins, Glen P Martin, and Niels Peek. Explicit causal reasoning is needed to prevent prognostic models being victims of their own success. *Journal of the American Medical Informatics Association*, 26(12):1675–1676, 2019.
- Adarsh Subbaswamy and Suchi Saria. From development to deployment: dataset shift, causality, and shift-stable models in health ai. *Biostatistics*, 21(2):345–352, 2020.
- Mark J Van der Laan, Eric C Polley, and Alan E Hubbard. Super learner. Statistical applications in genetics and molecular biology, 6(1), 2007.
- Robert A Verheij, Vasa Curcin, Brendan C Delaney, and Mark M McGilchrist. Possible sources of bias in primary care electronic health record data use and reuse. *Journal of medical Internet research*, 20(5):e185, 2018.
- Emma Wallace, Ellen Stuart, Niall Vaughan, Kathleen Bennett, Tom Fahey, and Susan M Smith. Risk prediction models to predict emergency hospital admission in community-dwelling adults: a systematic review. *Medical care*, 52(8):751, 2014.
- Emma Wallace, Susan M Smith, Tom Fahey, and Martin Roland. Reducing emergency admissions through community based interventions. *BMJ*, 352, 2016.
- World Health Organization. International statistical classification of diseases and related health problems, volume 1. World Health Organization, 2004.

Development and assessment of a machine learning tool for predicting emergency admission in Scotland

James Liley $^{1,2,3,*,\perp}$, Gergo Bohner 1,4,* , Samuel R. Emerson 3 , Bilal A. Mateen 1,5 , Katie Borland 6 , David Carr 6 , Scott Heald 6 , Samuel D. Oduro 6b , Jill Ireland 6 , Keith Moffat 6,7 , Rachel Porteous 6 , Stephen Riddell 6b , Simon Rogers 8,9 , Ioanna Thoma 1,2 , Nathan Cunningham 1,9 , Chris Holmes 1,10 , Katrina Payne 1 , Sebastian J. Vollmer 1,4 , Catalina A. Vallejos $^{1,2,\perp}$, and Louis J. M. Aslett $^{1,3,\perp}$

ABSTRACT

Emergency admissions (EA), where a patient requires urgent in-hospital care, are a major challenge for healthcare systems. The development of risk prediction models can partly alleviate this problem by supporting primary care interventions and public health planning. Here, we introduce SPARRAv4, a predictive score for EA risk that will be deployed nationwide in Scotland. SPARRAv4 was derived using supervised and unsupervised machine-learning methods applied to routinely collected electronic health records from approximately 4.8M Scottish residents (2013-18). We demonstrate improvements in discrimination and calibration with respect to previous scores deployed in Scotland, as well as stability over a 3-year timeframe. Our analysis also provides insights about the epidemiology of EA risk in Scotland, by studying predictive performance across different population sub-groups and reasons for admission, as well as by quantifying the effect of individual input features. Finally, we discuss broader challenges including reproducibility and how to safely update risk prediction models that are already deployed at population level.

Keywords: Emergency admission, Primary care, Machine learning

¹Alan Turing Institute, London, UK

²MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK

³Department of Mathematical Sciences, Durham University, UK

⁴Mathematics Institute, University of Warwick, UK

⁵Institute of Health Informatics, University College London, UK, and Wellcome Trust, London, UK

⁶Public Health Scotland (PHS). (b): former employee

⁷University of St Andrews, UK

⁸ National Services Scotland, UK

⁹School of Computing Science, University of Glasgow, UK

¹⁰Department of Statistics, University of Warwick, UK

¹¹Department of Statistics, University of Oxford, UK

^{*}Equal contribution

[⊥]Corresponding

CONTENTS

Supplementary Tables S2**S17 Supplementary Figures Supplementary Notes S23** S23 **S**2 **S**3 **S**4 **S**5

SUPPLEMENTARY TABLES

Section	Item	Checklist item	Section	Page
		Title and abstract		
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target	Title	-
Abstract	2	population, and the outcome to be predicted. Provide a summary of objectives, study design, setting, participants, sample size, predictors,	Abstract	-
		outcome, statistical analysis, results, and conclusions.		
		Introduction		
Background	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Introduction	3
and objectives	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	Introduction	3
	<u>'</u>	Methods		
	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	M: Overview and cohort details; M: Feature engineer- ing	4, 10
Source of data	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	M: Overview and cohort details	4
	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	M: Feature engineering	10
Participants	5b	Describe eligibility criteria for participants.	M: Overview and cohort details	4
	5c	Give details of treatments received, if relevant.	-	-
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	M: Overview and cohort details	4
Outcome	6b	Report any actions to blind assessment of the outcome to be predicted.	-	-
Predictors	7a	Clearly define all predictors used in develop- ing or validating the multivariable prediction model, including how and when they were mea- sured.	M: Feature engineering, table of predictors	10, table S3
Tredictors	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	-	-
Sample size	8	Explain how the study size was arrived at.	Introduction	4
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Supp: Missing values	10

	10a	Describe how predictors were handled in the	M: Machine learn-	13
		analyses.	ing prediction	
	10b	Consider type of model all model building me	methods M: Machine	12.14
	100	Specify type of model, all model-building procedures (including any predictor selection), and	M: Machine learning predic-	13,14
		method for internal validation.	tion methods; M:	
		method for internal varidation.	Cross-validation	
	10c	For validation, describe how the predictions	M: Cross-	14
		were calculated.	validation	
Statistical	10d	Specify all measures used to assess model per-	M: Predictive per-	14
analysis		formance and, if relevant, to compare multiple	formance	
methods		models.		
	10e	Describe any model updating (e.g., recalibra-	M: Model updat-	24
		tion) arising from the validation, if done.	ing	
Risk groups	11	Provide details on how risk groups were cre-	-	-
D 1	10	ated, if done.	D. D.L.	
Development	12	For validation, identify any differences from	D: Relation to	9
vs. validation		the development data in setting, eligibility cri-	other studies	
		teria, outcome, and predictors. Results		
	13a	Describe the flow of participants through the	M: Feature engi-	10, fig-
	13a	study, including the number of participants with	neering, figure 1	ure 1
		and without the outcome and, if applicable, a	neering, ngure r	uic i
		summary of the follow-up time. A diagram		
		may be helpful.		
	13b	Describe the characteristics of the participants	M: Overview and	4, 10, fig-
		(basic demographics, clinical features, avail-	cohort details; M:	ure 1
		able predictors), including the number of par-	Feature engineer-	
		ticipants with missing data for predictors and	ing, figure 1	
Participants		outcome.		
	13c	For validation, show a comparison with the	Not applicable;	Not appli-
		development data of the distribution of impor-	see discussion	cable; see
		tant variables (demographics, predictors and		page 9
	1.4	outcome).	M. O	4
Model	14a	Specify the number of participants and out-	M: Overview and cohort details	4
development	14b	come events in each analysis. If done, report the unadjusted association be-	conort details	_
development	140	tween each candidate predictor and outcome.	_	_
	15a	Present the full prediction model to allow pre-	Not possible: see	Not possi-
	154	dictions for individuals (i.e., all regression co-	code and data	ble: see
		efficients, and model intercept or baseline sur-	availability note	page 26
Model		vival at a given time cutoff).		
specification	15b	Explain how to the use the prediction model.	D: Implications	9
			for clinicians and	
			medical policy	
Model perfor-	16	Report performance measures (with CIs) for	R: Overall predic-	4
mance		the prediction model.	tive performance	
Model-	17	If done, report the results from any model up-	M: Model updat-	24, 4
updating		dating (i.e., model specification, model perfor-	ing; R: Overall	
		mance).	predictive perfor-	
		<u> </u>	mance	
Limitadiana	10	Discussion	D. Imaliant	0
Limitations	18	Discuss any limitations of the study (such as	D: Implications	9
		nonrepresentative sample, few events per predictor, missing data).	for clinicians and medical policy	
		dictor, missing data).	medical policy	

	19a	For validation, discuss the results with refer-	D: Relation to	9
		ence to performance in the development data,	other studies	
Interpretation		and any other validation data.		
Interpretation	19b	Give an overall interpretation of the results,	D: Relation to	9
		considering objectives, limitations, results from	other studies	
		similar studies, and other relevant evidence.		
Implications	20	Discuss the potential clinical use of the model	D: Implications	9
		and implications for future research.	for clinicians and	
			medical policy	
Other information				
Supplementary	21	Provide information about the availability of	Supplementary	24
information		supplementary resources, such as study proto-	material index	
		col, Web calculator, and data sets.		
Funding	22	Give the source of funding and the role of the	Acknowledgements	26
		funders for the present study.		

Table S1. TRIPOD guidelines and pages where discussed [Moons et al., 2015]

Type	Name	Description	Records	Individuals	Records Individuals End of pre-prediction (before start of risk year)
	PIS	GP prescribing information	393,573,549	5,589,772	5,589,772 One month based upon the Paid Date
	SMR00	Outpatient attendances	27,463,987	3,753,240	One day based upon the Clinic Date
	SMR01	Acute inpatients and day cases	26,326,889	2,205,606	One day based upon the Date of Admission
D EIID	SystemWatch	Urgent care monitoring	12,890,591	1,750,009	One day based upon the Date of Admission
Naw Enk	A&E2	Accident and emergency records	7,539,454	3,031,773	One day based upon the Date of Arrival
	SMR01E	Geriatric long stay	137,340	25,015	
	SMR04	Mental health inpatient and day cases	111,487	51,635	51,635 One day based upon the Date of Admission
	All	All raw EHR tables combined	468,043,297	5,829,532	
Oth 2:	SPARRALTC	SPARRALTC Long-term conditions	3,286,987	1,978,171	-
Omer	Deaths	Mortality records	283,554	283,554	

Fable S2. Input data sources. The data comprises national EHR Scottish databases between 1 May 2013 and 30 April 2018. Each record corresponds to a single interaction with the (A&E2), Public Health Scotland [2020c] (System Watch) and Public Health Scotland [2020b] (PIS). The LTC table was derived by PHS from historic SMR01 tables with an admission pre-prediction period is 3 years for PIS, SMR00, SMR01, System Watch, A&E2, SMR01E and SMR04. All LTC records up to 01 January 1981 are used in the pre-prediction period health system. SMR - Scottish Morbidity Records. Information about specific EHR tables is available at Public Health Scotland [2023] (SMR datasets), Public Health Scotland [2020a] between 01 January 1981 and 30 April 2018. The Deaths table was provided to PHS by National Records of Scotland (NRS) and is up to date until TBC. The timescale for the The earlier end of the pre-prediction period is because the most recent month will not be generally available when running the predictions.

Class	Variable name	Name
Analysis only	time	Time cutoff
	target	Emergency admission in year
	\$ (((((((((((((((((((Mhother admitted or died or
	ווסמסנו	
	CV	Fold for cross-validation
Demographics	SexM	Male sex
	age	Age at time cutoff
	SIMD_DECILE_2016_SCT	SIMD decile
General	v3score	SPARRA version 3 score
Previous admissions	emergency_bed_days	Number of emergency bed days
	other_bed_days	Number of non emergency non
		elective bed days
	num_emergency_admıssıons	Number of emergency admis-
	elective_bed_days	sions Number of elective bed days
	num_elective_admissions	Number of elective admissions
	num_emergency_selfharm	Number of self harm related
		emergency admissions
	num_other_admissions	Number of non emergency non
		elective admissions
	num_alconol_substance_admissions	Number of emergency drug and alcohol-related admissions
	num_alcohol_admissions	Number of emergency alcohol-
		related admissions
	numLTCs_resulting_in_admin	Number of long-term conditions
		resulting in admission
	numLTCs_resulting_in_elective_admin	Number of long-term conditions
		resulting in elective admission
	numLTCs_resulting_in_emergency_admin	Number of long-term conditions
		resulting in emergency admis-
	numLTCs_resulting_in_other_admin	sion Number of long-term conditions
		resulting in non-emergency non-
		elective admission
	num_psych_admissions	Number of previous psychiatric
		admissions
	num_dc_admıssions	Number of previous day case ad-
		missions
	days.since.last.acute	Days since last acute admission of any type
	days.since.last.emergency.admission	Days since last emergency ad-
		mission

	days.since_last_elective_admission	Days since last elective admission
&E attendances	num_ae2_attendances	Number of previous A&E atten-
	num_alcohol_drug_attendances	Number of drug and alcohol re-
		lated A&E attendances
	num_psych_attendances	Number of psychiatric A&E attendances
	days_since_last_AE2	Days since last A&E attendance
escriptions	num_bnf_sections	Number of BNF sections from
	nim bnf total	which a prescription was filled Total number of filled prescrip-
		tions
	pis-respiratory	Number of respiratory-related
	pis-corticosteroids	prescriptions Number of corticosteroid pre-
	pis_antianaemics	scriptions Number of anti-anaemic pre-
		scriptions
	pis-cns	Number of central nervous sys-
	pisbronco	tem related prescriptions Number of bronchodilator pre-
		scriptions
	pis_infections	Number of infection related pre-
	pis-endocrine	scriptions Number of endocrine-related
		prescriptions
	pis_incontinence	Number of incontinence device
	pis-stoma	presciptions Number of stoma device pre-
	•	scriptions
	pis-anticoagulant	Number of anticoagulant and protamine prescriptions
	pis-antibacterial	Number of antibacterial prescrip-
		tions
	pis-antiepileptic_Drugs	Number of antiepileptic prescrip-
	pis-antifibrinolytic	uons Number of antifibrinolytic and
		haemostatic prescriptions
	pis-antisecretory	Number of antisecretory and mu-
		cosal protectant prescriptions
	pıs-gut_motılıty	Number of antispasmodic and
		gut-mounty aneming presenty-
	pis-diuretics	Number of diuretic prescriptions

pis-lipid	Number of lipid-lowering drug
1	prescriptions
pis bandages	Number of arm sling bandage
pis-catheters pis-antiplatelets	prescriptions Number of catheter prescriptions Number of antiplatelet prescrip-
pis_respiratorv_corticosteroids	tions Number of respiratory corticos-
pis-dementia	teroid prescriptions Number of dementia-related pre-
pis-skin	scriptions Number of skin condition pre-
	scriptions
pis-hypertensive_heart_failure	Number of hypertensive heart failure prescriptions
pis_intestinal	Number of prescriptions for
	E 2
pis-diabetes	Number of prescriptions for
ojs neuromuscular	drugs used in diabetes mellitus Number of prescriptions for
	drugs used in neuromuscular dis-
	orders
pis-parkinsonism	Number of prescriptions for
	drugs used in Parkinsonism and related disorders
pis-sub-depend	Number of prescriptions for
	drugs used in substance depen-
pis-fluids	dence Number of fluid and electrolyte
,	prescriptions
pis_minerals	Number of mineral prescriptions
PISTRUCOTYCICS	tions
pis_nose	Number of drugs acting on the
	nose prescriptions
pis-gastro-int	Number of gastrointestinal drug
nis hetablockers	prescriptions Number of beta-blocker prescrip-
	tions
pis-antianginal	Number of antianginal prescrip-
	tions Number of oral nutrition pre-
1. C + C + C + C + C + C + C + C + C + C	scriptions

	pis_sex_hormone_antagonists	Number of sex hormone antago-
		stions
	pıs-genıtourınary	Number of genitourinary pre-
	pis-inotropic	scriptions Number of inotropic prescrip-
		tions
	pis-ear	Number of ear prescriptions
	pis-glaucoma	Number of glaucoma prescrip-
	pis-antibacterial-eyes	Number of eye antibacterial pre-
	pis-ophthalmic	scriptions Number of ophthalmic prescrip-
	x:. 0	tions Number of antiinflammatory cor.
	Pro-ancremination y-corerona	ticosteroid prescriptions
	pis_cromo	Number of cromoglycate pre-
		scriptions
	pıs_oropharynx	Number of oropharyngeal pre- scriptions
	pis-antiarrhythmics	Number of antiarrhythmic pre-
	-	scriptions
	pis_immune	Number of immunomodulatory
	pis-hosiery	Number of hosiery prescriptions
	pis-cytotoxics	Number of cytotoxics prescrip-
		tions
	pis-supplements	Number of supplement prescrip- tions
	pismydriatics	Number of mydriatics prescrip-
	۲. ۲. د ا	tions Number of food prescriptions
	pisioca pis.metabolic	Number of metabolic prescrip-
	pis-local-anaesthetics	tions Number of local anaesthetic pre-
		scriptions
	pis-rheumatic	Number of rheumatic disease
	(prescriptions
3-term conditions	pis vicanitis	Number of recorded long term
		conditions
	parkinsons_indicated	Parkinsons disease indicated by
		admission records or medication
	diabetes_indicated	Diabetes indicated by admission
		records or medication

Previous congenital problems di-Previous chronic obstructive pul-Dementia indicated by admis-Previous digestive disorder diag-Previous chronic liver disease di-Years since first digestive disor-Multiple sclerosis indicated by admission records or medication Epilepsy indicated by admission Previous endocrine or metabolic Previous blood disease diagnosis Previous atrial fibrillation diag-Previous diabetes mellitus diag-Previous heart disease diagnosis Previous Parkinsons disease di-Previous cerebrovascular disease Years since first arthritis diagno-Years since first congenital prob-Years since first endocrine or Years since first blood disease Previous heart failure diagnosis Previous multiple sclerosis diag-Previous renal failure diagnosis Previous dementia diagnosis metabolic disease diagnosis Previous epilepsy diagnosis Previous arthritis diagnosis sion records or medication Previous asthma diagnosis Previous cancer diagnosis monary disease diagnosis records or medication disease diagnosis lems diagnosis der diagnosis diagnosis diagnosis agnosis agnosis agnosis nosis nosis nosis ltc_FIRST_CONGENITAL_PROBLEMS_EPISODE_yearssincediag ltc_FIRST_OTHER_DIGESTIVE_EPISODE_yearssincediag ltc_FIRST_ENDOCRINE_MET_EPISODE_yearssincediag ltc_FIRST_ARTHRITIS_EPISODE_yearssincediag ltc_FIRST_DIS_BLOOD_EPISODE_yearssincediag CEREBROVASCULAR_DISEASE CHRONIC_LIVER_DISEASE CONGENITAL_PROBLEMS ATRIAL-FIBRILLATION epilepsy_indicated MULTIPLE_SCLEROSIS dementia_indicated PARKINSON_DISEASE OTHER_DIGESTIVE HEART_DISEASE HEART_FAILURE RENAL-FAILURE ENDOCRINE_MET MS_indicated ARTHRITIS DIS_BLOOD DEMENTIA DIABETES EPILEPSY ASTHMA CANCER COPD

ltc_FIRST_ASTHMA_EPISODE_yearssincediag	Years since first asthma diagno-
ltc.FIRST.ATRIAL.FIBRILLATION.EPISODE.yearssincediag	sis Years since first atrial fibrillation
ltc.FIRST.CANCER.EPISODE.yearssincediag ltc.FIRST.CHRONIC.LIVER.DISEASE.EPISODE.yearssincediag	diagnosis Years since first cancer diagnosis Years since first chronic liver dis-
ltc_FIRST_COPD_EPISODE_yearssincediag	ease diagnosis Years since first chronic obstruc-
ltc.FIRST.DEMENTIA.EPISODE.vearssincediag	tive pulmonary disease diagnosis Years since first dementia diag-
ltc_FIRST_DIABETES_EPISODE_vearssincediag	nosis Years since first diabetes melli-
ltc_FIRST_EPILEPSY_EPISODE_yearssincediag	tus diagnosis Years since first epilepsy diagno-
ltc_FIRST_HEART_DISEASE_EPISODE_yearssincediag	sis Years since first heart disease di-
ltc.FIRST.HEART.FAILURE.EPISODE.yearssincediag	agnosis Years since first heart failure di-
ltc.FIRST.MULTIPLE.SCLEROSIS.EPISODE.yearssincediag	agnosis Years since first multiple sclero-
ltc_FIRST_PARKINSON_DISEASE_EPISODE_yearssincediag	sis diagnosis Years since first Parkinsons dis-
ltc.FIRST.RENAL.FAILURE.EPISODE.yearssincediag	ease diagnosis Years since first renal failure di-
ltc.FIRST.CEREBROVASCULAR.DISEASE.EPISODE.yearssincediag	agnosis Years since first cerebrovascular
ltc.total.count	disease diagnosis Number of recorded long term
	conditions
num_outpatient_appointment_general	Number of previous first outpa-
num_outpatient_appointment_psych	Number of previous first psychi-
num_outpatient_appointment_followup_psych	atric outpatient appointments Number of previous follow-up
1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	psychiatric outpatient appoint-
num_outpatient_appointment_followup_general	ments Number of follow-up outpatient
	appointments
days_since_last_SMRU0	Days since last outpatient attendance
days_since_last_SMR04	Days since last mental health and day case attendance

Outpatients

Table S3. Definition of input features for SPARRAv4. Variable names match the names used in our analysis code.

Words	Label
Antihist, Hyposensit & Allergic Emergen Drugs Acting On The Nose Corti'roids & Other Anti-Inflamm.Preps. Nasal Products	Nasal allergies
Contraceptives Miscellaneous Ophthalmic Preparations Eye Products Antiviral Drugs Corti'roids & Other Anti-Inflamm.Preps. Anti-Infective Eye Preparations	Eye products
Antidepressant Drugs Antibacterial Drugs	
(BNF) Unknown	
Wound Management & Other Dressings Drugs Used In Neuromuscular Disorders Antibacterial Drugs Skin Fillers And Protectives Night Drainage Bags Catheters Leg Bags Stockinette Arm Sling/Bandages Surgical Adhesive Tape Swabs Irrigation Solutions Urinary tract infection, site not specified Essential (primary) hypertension	Wound management
Hypnotics And Anxiolytics Drugs Used In Substance Dependence	Substance Abuse and Mental Health
Acne and Rosacea Sex Hormones & Antag In Malig Disease Hypothalamic&Pituitary Hormones&Antioest Antibacterial Drugs Chemotherapy session for neoplasm Malignant neoplasm, breast, unspecified	
Antiplatelet Drugs Lipid-Regulating Drugs	Metabolic syndrome
Oral Nutrition Preparations For Warts And Calluses Top Local Anaesthetics & Antipruritics Vaccines And Antisera Anti-Infective Skin Preparations Other Appliances Anthelmintics Anti-Infective Eye Preparations Cough Preparations Drugs Acting On The Oropharynx Antiperspirants Base/Dil/Susp Agents/Stabilisers Other chemotherapy Viral infection, unspecified	Skin disease

Cl	nyroid And Antithyroid Drugs NS Stimulants and drugs used for ADHD ntibacterial Drugs	
Aı	nalgesics	
An Dr Tro	ntibacterial Drugs nti-Infective Skin Preparations rugs Acting On The Oropharynx reatment Of Vaginal & Vulval Conditions ntifungal Drugs rugs Acting On The Ear opical Corticosteroids ough Preparations nti-Infective Eye Preparations	
Hy	ypertension and Heart Failure	
Cł Aı	naemias + Other Blood Disorders nronic Bowel Disorders ntifibrinolytic Drugs & Haemostatics ytotoxic Drugs	
Dr Dr Ac Ile Ac Cc Sv	yspep&Gastro-Oesophageal Reflux Disease rugs Used In Psychoses & Rel.Disorders rugs Used In Park'ism/Related Disorders cute Diarrhoea costomy Bags dhesive Removers (Sprays/Liquids/Wipes) blostomy Bags vabs cin Fillers And Protectives	Stoma care
Er To	mollient & Barrier Preparations opical Corticosteroids mollients	Skin and scalp disorders
Sh Pr	nampoo&Other Preps For Scalp&Hair Cond eparations For Eczema And Psoriasis nti-Infective Skin Preparations	
Dr Flu Mr Su Ar	orticosteroids (Endocrine) rugs Affecting The Immune Response uids And Electrolytes inerals unscreens And Camouflagers ntibacterial Drugs cute Diarrhoea	
	ntisecretory Drugs+Mucosal Protectants	
Li	pid-Regulating Drugs	
Be	eta-Adrenoceptor Blocking Drugs	
	rugs For Genito-Urinary Disorders	

ICD10 code begins with:	Admission type
A;B	Infectious disease
C	Neoplasm
D1;D2;D3;D4	Neoplasm
D5;D6;D7;D8;D9	Blood
E	Endocrine/metabolic
F	Mental/behavioural
G	Nervous system
H1;H2;H3;H4;H5	Eye
H6;H7;H8;H9	Ear
I	Circulatory
J	Respiratory
K	Digestive
L	Skin
M	Musculoskeletal
N	Genitourinary
O	Obstetric/puerperium
P	Perinatal
Q	Congenital
R	Abnormality NEC
S;T;V;X;Y	External
U;Z	Other

Table S5. Definition of different admission types.

Antibacterial Drugs	
Anticoagulants And Protamine Treatment Of Glaucoma Positive Inotropic Drugs Anti-Arrhythmic Drugs Atrial fibrillation and flutter	Arrhythmias
Nit,Calc Block & Other Antianginal Drugs	
Soft-Tissue Disorders & Topical Pain Rel Local Anaesthesia Analgesics Elastic Hosiery Dry Mouth Products	
Acute Diarrhoea	

Table S4. Exploration of the inferred topics. Details of derived topics for topic model used for prediction in F1 (fitted to F2+F3). A topic model assumes that each 'document' (individual) in a 'corpus' (population) is associated with various 'topics' (roughly, illness categories) where each topic corresponds to a distribution over 'words' (ICD10 codes and medication types). We would expect that the 30 topics fitted to each fold roughly represent the major clusters of disease types which occur amongst those individuals. This tables shows the 'words' with the highest probability of membership in each topic (> 1%, where probabilities over all words sum to 100%). In each topic, words are ordered by decreasing probability of topic membership. ICD10 codes are italicised; medication types are not. Topics are ordered by decreasing importance (mean absolute Shapley value). We manually assigned labels to some topics which appear to code for particular disease types.

	Total	Admitted only	Died	Both
Excluded	4,622,512	128,241	6,139	3,166
Included	12,866,084	977,159	57,183	107,827
Died	585,322	0	0	0
No v3	4,528,514	121,857	6,036	3,011
No SIMD	199,746	12,688	151	263
Unmatched	13,524	526	0	0
Died and No v3	585,089	0	0	0
Died and No SIMD	1,258	0	0	0
Died and Unmatched	0	0	0	0
No v3 and No SIMD	112,992	6,648	48	110
No v3 and Unmatched	6,468	179	0	0
No SIMD and Unmatched	303	20	0	0
Died and No v3 and No SIMD	1,258	0	0	0
Died and No v3 and Unmatched	0	0	0	0
Died and No SIMD and Unmatched	0	0	0	0
No v3 and No SIMD and Unmatched	258	17	0	0
All	0	0	0	0

Table S6. Frequency of EA and deaths amongst samples excluded from SPARRAv4. All figures show total numbers. In row names, as for Figure 1B: 'Died': Died prior to time cutoff; 'No SIMD': missing SIMD; 'No v3': missing SPARRAv3 score; 'Unmatched': could not match record. For completeness, combinations of exclusions are included even if no individual was excluded with this particular combination.

	Fold 1			
	YED	U16	FEC	LTC
ANN	0	0	0	0
Penalised GLM	0	0	0	0
Naive Bayes	0	0	0	0
RF, depth: 20	0	0	0.24	0.07
RF, depth: 40	0.18	0.21	0.17	0.23
SPARRAv3	0	0	0	0
XGB depth:3	1.86	1.57	1.24	1.69
XGB depth:4	0.84	1.57	0.68	0.62
XGB depth: 8	3.12	3.20	2.14	2.39
		D-1	10	
	YED	Fol U16	a z FEC	LTC
ANN	0	0	0	0
Penalised GLM	$\begin{bmatrix} 0 \\ 0 \end{bmatrix}$	0	0	0
	0	0	0	0
Naive Bayes RF, depth: 20	$\begin{bmatrix} 0 \\ 0 \end{bmatrix}$	0	0.09	0.01
RF, depth: 40	0.22	0.20	0.09	0.01
SPARRAv3	0.22	0.20	0.24	0.10
XGB depth:3	1.87	1.58	1.37	1.62
XGB depth:4	0.88	1.72	0.68	0.74
XGB depth: 8	3.02	3.45	2.07	2.47
AGB deptil. 8	3.02	3.43	2.07	2.47
		Fol	d 3	
	YED	U16	FEC	LTC
ANN	0	0	0	0
Penalised GLM	0	0	0	0
Naive Bayes	0	0	0	0
RF, depth: 20	0	0	0.28	0
RF, depth: 40	0.16	0.11	0.15	0
SPARRAv3	0	0	0	0
XGB depth:3	1.73	1.16	1.31	1.60
XGB depth:4	1.07	1.82	0.67	0.48
XGB depth: 8	3.02	3.42	2.06	2.44

Table S7. Coefficients of ensemble when fitted separately to SPARRA*v*3 **cohorts**. Columns YED, U16, FEC, and LTC correspond to subcohorts in SPARRA*v*3; please see Methods.

SUPPLEMENTARY FIGURES




Figure S1. Extended data overview. Distribution of the number of input EHR entries (prior to exclusions) according to age, sex and SIMD deciles (1: most deprived; 10: least deprived) stratified by the input database. All sub-panels are drawn to the same scale. "Other" includes geriatric long stay (SMR01E) and urgent care monitoring (System Watch). (B) Distribution of target events by age stratified by event type.




Figure S2. Density plot comparing SPARRAv3 and SPARRAv4 scores. The test datasets used within each CV iteration were combined in order to generate this plot (i.e. all samples are included once). Joint density (low to high: white-grey-red-yellow) of individual SPARRAv3 and SPARRAv4 scores. The density is normalised to uniform marginal on the Y axis, then the X axis; true marginal distributions of risk scores are shown alongside in grey.




Figure S3. Calibration curves for SPARRAv4 model constituents. Estimates obtained for the test set within each CV iteration are shown in different colours (legend shown in top left panel). Bottom sub-panels show departure from perfect calibration.




Figure S4. Performance of a static model and static scores used to predict risk at future time cutoffs. (A-C) Performance of static scores evaluated using M_0 at time t_0 for predicting EA at times $t_1 - t_5$. (A) ROC curves. (B) PR curves. (C) Calibration curves. (D) AUROCs for scores calculated at each time cutoff (based on M_0) for prediction in subsequent time cutoffs.




Figure S5. Feature importance. (A-B) Two examples of non-linear feature importance as measured by mean Shapley values (vertical lines show plus/minus one standard deviation). (C) Distribution of Shapley values for the number of previous elective and emergency admissions. (D-E) Comparison of predictive performance with and without topic-model derived features. (D) ROC. (E) PRC. (F) Calibration curve. For (D-E), bottom sub-panels show differences in sensitivity and specificity, respectively. In (F) bottom sub-panel shows difference with respect to perfect calibration.

SUPPLEMENTARY NOTES

S1 Analysis of specific topic effects

We searched for individuals for whom the topic model made a substantial difference to their SPARRA score. We considered Shapley values for the 30 topic features across 20,000 uniformly-randomly-chosen individuals in cross-validation fold 1. We searched for topic-derived features for which some of these 20,000 individuals had a Shapley value in excess of 2% for that topic. This is a large Shapley value; for reference, the mean Shapley value from being in the most-deprived decile is only around 1%.

We noted that for one topic feature (topic 21) 87 individuals (about 0.43% of the cohort of 20,000) had a Shapley value in excess of 2%, meaning that the additive contribution to their score from the topic feature was at least 0.02. To gauge the effect of this change, we compared the SPARRA ν 3 and SPARRA ν 4 scores of these individuals (the SPARRA ν 3 score does not use features derived from a topic model). The SPARRA ν 4 scores were on average higher (mean 0.52 for SPARRA ν 4 vs 0.40 for SPARRA ν 3; p-value (t-test) $< 1 \times 10^{-4}$) and calibration-in-the-large was closer for SPARRA ν 4 (admission frequency 0.56; closer to 0.52 (SPARRA ν 4) than 0.40 (SPARRA ν 3)).

Topic 21 was associated with skin and scalp disorders (see Supplementary Table S4). It is possible that the individuals for whom this topic feature had a high Shapley value were at elevated risk of EA due to such disorders, but that this was not detectable from the features used in SPARRAv3.

In order to avoid data leakage while using our cross-validation scheme, we needed to fit three separate topic models, each fitted to data from two cross-validation folds and used to generate topic features for the remaining fold (see Methods section). For the deployed model, a topic model is refitted to the entire cohort, so the inferred topics are unlikely to contain the exact same cluster of prescriptions and diagnosis. Furthermore, topic-specific contributions may differ from those presented here. However, the analysis above does indicate that, in general, topic features can lead to substantial improvements in score accuracy for some individuals.

S2 Model re-calibration

We applied a monotonic transformation to optimise the calibration of the scores generated by the ensemble. Given a predicted value \tilde{Y} (for ease of notation we do not explicitly include its dependency on the input features X) we defined a transformation $m(\cdot)$ to optimise calibration, essentially using isotonic regression. The latter was derived using the following procedure.

Fitst, we defined an empirical calibration function for an estimator \tilde{Y} of Y|X:

$$CAL_{\tilde{Y}}(y) = \operatorname{mean}\left(\tilde{Y} \middle| \left(|\tilde{Y} - y| < \frac{1}{100} \right) \right)$$

$$\approx \mathbb{E}_{Y|X}\left(Y \middle| \tilde{Y} = y\right) \tag{1}$$

We then found a,b such that the mean and mode of $(a\tilde{Y}+b)$ were approximately correctly calibrated; that is, $CAL_{a\tilde{Y}+b}(y)=y$ for $y\in\{\text{mean}(a\tilde{Y}+b),\text{mode}(a\tilde{Y}+b)\}$, and scaled a,b such that $0\leq a\tilde{Y}+b\leq 1$. Across an evenly spaced grid G of 100 y-values we computed the function:

$$c(y) = (1 - 10^{-5}) \max_{y' \in G; y' \le y} CAL_{a\tilde{Y} + b}(y') + 10^{-5}y$$
(2)

using the cumulative maximum of $CAL(\cdot)$ to ensure $c(\cdot)$ is non-decreasing, and adding a linear term to ensure $c(\cdot)$ is increasing. We extended the domain of $c(\cdot)$ to [0,1] using piecewise linear interpolation, and defined our calibrating transform $m(\cdot)$ as the inverse of $c(\cdot)$:

$$m(y) = c^{-1}(ay + b)$$
 (3)

The transformation above was optimised using by further splitting the training set (F1+F2) within our 3-fold cross-validation (CV) procedure (we use F1, F2 and F3 to denote each fold). For each CV-fold, the following steps were performed:

- 1. Train all constituent models using F1 (except SPARRAv3, for which PHS provided the scores).
- 2. Each constituent model was then used to generate scores for samples in F2.
- 3. Given those scores, ensemble weights were inferred via 10-fold CV within F2.
- 4. Using the previously calculated scores and ensemble weights, the parameters a and b were chosen to optimise calibration in F2.
- 5. The optimal ensemble weights and calibration transformation parameters (*a* and *b*) were then used as fixed constants when training the model in the combined F1+F2 dataset.

Note that, due to computational constrains, the topic model was not retrained within the above procedure. Instead, a pre-trained topic model (using F1+F2 as a combined dataset) was used to generate features to be used in step 1.

S3 Use of subcohort-specific ensemble coefficients

When fitting the SPARRAv4 score, for each cross-validation fold, we computed predictions for a range of constituent machine learning models. The final score was defined as a linear combination of the predictions generated by each constituent model a(see Methods section and Table 2). The optimal linear combination was determined by fitting an L-1 penalised generalised linear model with the predictions from the constituent models as input and presence of EA as output.

We considered the possibility that the model could be improved by allowing the coefficients of each model to vary across different subsets of the population. In particular, we assessed the extent to which allowing models to vary across the subcohorts used in the SPARRAv3 score (LTC, YED, FEC, and U16; see Methods section) improved the overall performance of the model. We fitted separate penalised regression models (leading to different ensemble weights) in each of the three cross-validation folds and four cohorts (for 12 overall). Subsequently, we assessed how predictive performance changed in the corresponding subcohort in the test set. For instance, we fit one linear model to samples in the YED cohort in folds 2 and 3, and evaluated the performance of this model in samples in the YED cohort in fold 1.

For comparison, we also considered the performance of our original non-cohort-specific ensemble weights, the performance of the best constituent model, and the performance of our original model without topic-model derived features. We evaluated all models using AUROC.

We found that using cohort-specific coefficients in this way improved AUC in the relevant test sets (of 12 comparisons of AUROC, 11 improved; p < 0.007 using a Binomial test). However, the magnitude of the change was small: AUC improved in each subcohort by a mean value of only 3.8×10^{-5} (where the mean is across cross-validation folds and cohorts). By comparison, use of topic features improves AUC by a mean of 4.1×10^{-4} , around ten times higher, and use of a weighted sum of models rather than just the best-performing constituent model improves AUC by 7.7×10^{-4} , around twenty times higher.

Given the relatively small advantage of doing this relative to the difficulty of implementation, we opted not to fit separate models in subcohorts in this way. However, this remains an active area of further research.

Table S7 details the coefficients attained in each model. Generally, the same models (XGB and RF) had non-zero coefficients in each case.

S4 Imputation of lengths of stay when discharge date was missing

Some of our predictors concerned lengths-of-stay; that is, total days spent in hospital in the pre-prediction period (elective_bed_days, emergency_bed_days, and other_bed_days; see Table S3). In general, these were calculated by finding all stays listed for a given individual, subtracting the admission date from the discharge date for each stay, and summing the results across all stays. However, for some hospital stays, no discharge date was present in the source tables. In some cases, this was due to the individual still being in hospital at the time cutoff, but in others was evidently due to the discharge date simply not being recorded; we identified several individuals who were admitted with no discharge date who had evidence of community activity during the time they were supposedly in the hospital. To manage this, we used an imputation procedure for hospital stays in which the discharge date was not recorded. When we see an individual at a time cutoff t with admission date d and no discharge date, we have options of:

- 1. Do not count this admission towards the total length of stays; that is, count the stay length as 0 days for that admission. This will under-estimate the total length of stay.
- 2. Count time t d towards the total length of stay. Effectively this imputes the discharge date using the time cutoff. This could lead to incorrect assumptions of very long hospital stays for individuals; indeed, since the pre-prediction period is three years, the mean assumed hospital stay length for such patients would be in excess of eighteen months. This is likely to over-estimate the total length of stay.
- 3. Count some arbitrary time t_0 towards the total length of stay. Depending on the value of t_0 , the total length of stay may be under- or over-estimated.

All of these options coult potentially decrease the usefulness of these variables by artificially inflating (or deflating) the predicted EA risk. As a compromise, we decided to use

$$\min(t - d, t_0) \tag{4}$$

as the length of stay for admissions with a missing discharge date. Effectively, this strategy uses t_0 as a default *minimum length* for stays with missing discharge date.

To choose t_0 , we use an empirical Bayes-optimal decision rule. Let E be the event that the discharge time for a given admission is not recorded. We model the time t-d as a (discrete) random variable X with a mixture distribution depending on E. We want to choose t_0 so that $P(E|X=x) \ge 1/2$ if and only if $x \ge t_0$. We set

$$P(X = x | \neg E) = f(x)$$

 $P(X = x | E) = \frac{1}{3 \times 365.25} = c$

that is; if the discharge time is recorded (in which case the individual is genuinely still in hospital at time t), we have some distribution of true lengths of stay, whereas if the discharge time is not recorded, the time t-d has an equal probability of being anywhere between one day and three years.

Let P(E) = q. Now

$$P(E|X=x) = P(X=x|E)\frac{P(E)}{P(X=x)} = \frac{cq}{cq + (1-q)f(x)}$$
(5)

Given estimates of q and $f(\cdot)$, to find t_0 we may set this expression to 1/2 and solve for x.

In order to estimate q and f with \hat{q} and \hat{f} , we consider the population P of admissions (not individuals) where the admission date is between May 2013 and May 2014. We then estimate

 \hat{q} = proportion of P with no recorded discharge date or discharged after May 2016

 $\hat{f}(x)$ = proportion of P with recorded discharge date before May 2016 with length of stay x

We use this population of admissions so as to avoid data leakage, since these are prior to the earliest time cutoff (May 2016) used in fitting the model. This is also our rationale for treating individuals who were discharged post-May 2016 the same as having no recorded discharge date: we cannot use this information without data leakage. However, we note that the number of individuals with genuine > 2 year hospital stays is very small.

Following this procedure, estimated values of t_0 are 26, 19 and 6 for emergency_bed_days, elective_bed_days and other_bed_days, respectively.

S5 Assessment of calibration

We use an estimator for calibration broadly based on the Nadaraya-Watson kernel estimator [Nadaraya, 1964, Watson, 1964]. We re-derive several properties (consistency, bias) to highlight their interpretation in our context.

We assume in general that, for IID predictor/outcome pairs $(X_i, Y_i) \sim (X, Y)$, $i \in 1..n$, and an optimal predictor function p_{opt} , we have

$$Y|X \sim \text{Bernoulli}[p_{out}(X)]$$
 (6)

noting that this implies

$$p_{opt}(X) = E[Y|p_{opt}(X)] \tag{7}$$

We want to estimate $p_{opt}(X)$.

Since we only observe Y = 1 or Y = 0, we must estimate E[Y|p(X) = z] as some kind of average of Y about observed values p(X) close to z. A routine way to do this is to use 'reliability diagrams' [Bröcker and Smith, 2007] in which we bin values of p(X) and estimate E(Y|p(X)) in each bin.

Since for small bin sizes there may be few or no values of p(X) in some bins, we use a kernel estimate $\hat{c_p}(z)$ of $c_p(z) = E[Y|p(X) = z]$:

$$\hat{c_p}(z) = z \frac{\sum_i Y_i K_{\delta}[p(X_i), z]}{\sum_i p(X_i) K_{\delta}[p(X_i), z]} = \sum_i w_i Y_i$$
(8)

where $K_{\delta}:(0,1)^2 \to \mathbb{R}^+$ is some distance-measuring kernel with width δ , and

$$w_i = z \frac{K_{\delta}[p(X_i), z)]}{\sum_i p(X_i) K_{\delta}[p(X_i), z]}$$
(9)

We avoid the simpler estimate given by the K_{δ} -weighted mean of Y_i s:

$$\tilde{c_p}(z) = \frac{\sum_i Y_i K_{\delta}[p(X_i), z]}{\sum_i K_{\delta}[p(X_i), z]} \tag{10}$$

for reasons shown below. We note the following:

Proposition 1. If p(X) has Lesbegue-integrable positive density on (0,1), K(z,x) and $c_p(x)$ are Lesbegue-integrable functions of x for fixed z > 0, and the kernel 'narrows with δ ' so

$$E_X\{p(X)K_{\delta}[p(X),z]\} \xrightarrow{\delta \to 0} z$$

$$E_X\{c_p[p(X)]K_{\delta}[p(X),z]\} \xrightarrow{\delta \to 0} c_p(z)$$

then $\hat{c}(z)$ becomes a consistent estimator of c(z) as $\delta \to 0$

Proof. From Slutsky's lemma, the law of total expectation and the strong law of large numbers

$$\hat{c_p}(z) = z \frac{\sum_i Y_i K_{\delta}(p(X_i), z)}{\sum_i f(X_i) K_{\delta}(f(X_i), z)} \xrightarrow{p \to \infty} z \frac{E_X \left\{ c_p[p(X)] K_{\delta}[f(X), z] \right\}}{E_X \left\{ p(X) K_{\delta}[p(X), z] \right\}} \xrightarrow{\delta \to 0} z \frac{c_p(z)}{z} = c_p(z)$$

$$(11)$$

We note that $\hat{c}_p(Z)$ is not generally consistent if $\delta > 0$. However, the inconsistency is not severe: we note

Proposition 2. If, in addition to the above, $K_{\delta}(x,z) = K_{\delta}(x-z)$ is a symmetric density with second moment δ and negligible moments of higher order, and the densities of p(X) and $c_p(X)$ are twice differentiable at z, then $\hat{c_p}(z) \to c_p(z) + O(\delta^2)$

Proof. We have

$$E_{X}\{c_{p}[p(X)]K_{\delta}[p(X),z]\} = E_{x \sim p(X)}[c_{p}(x)K_{\delta}(x-z)]$$

$$= \int_{0}^{1} f_{p(X)}(x)c_{p}(x)K_{\delta}(x-z)dx$$

$$= \int_{0}^{1} (f_{p(X)}(z) + f'_{p(X)}(z)(x-z))(c_{p}(z) + c'_{p}(x-z))K_{\delta}(x-z)dx$$

$$+ \int_{0}^{1} O\left((x-z)^{2}\right)K_{\delta}(x-z)dx$$

$$= f_{p(X)}(z)c_{p}(z) + \int_{0}^{1} O\left((x-z)^{2}\right)K_{\delta}(x-z)dx$$

$$+ (f_{p(X)}(z)c'_{p}(z) + f'_{p(X)}(z)c_{p}(z)) \int_{0}^{1} (x-z)K_{\delta}(x-z)dz$$

$$= f_{p(X)}(z)c_{p}(z) + O\left(\delta^{2}\right)$$
(12)

noting the symmetry of K_{δ} . If we replace $c_p[p(X)]$ with p(X), the expectation is $zf_{p(X)}(z) + O(\delta^2)$, and the result follows from the first part of 11.

Remark 1. In the ideal case where $c_p(z) = z$ (that is, our model is perfectly calibrated) estimator 9 is consistent even when $\delta > 0$, whereas the apparently simpler asymptotically consistent (as $\delta \to 0$) estimator of a weighted sum of Y_i 's:

$$\tilde{c_p}(z) = \frac{\sum_i Y_i K_{\delta}[p(X_i), z)]}{\sum_i K_{\delta}[p(X_i), z]}$$
(13)

is not.

Finally, we note the following:

Proposition 3. Under the assumptions above, with fixed X_i , the bias of $\hat{c_p}(z)$ is

$$\frac{\sum_{i} B(X_{i}, z) K_{\delta}[p(X_{i}), z])}{\sum_{i} p(X_{i}) K_{\delta}[p(X_{i}), z]} = \sum_{i} w_{i} \frac{B(X_{i}, z)}{z}$$

$$(14)$$

where $B(X_i, z) = p(X_i)c_p(z) - zc_p(p(X_i))$.

Proof. With fixed X_i

$$\begin{split} E_Y[c_p(z) - \hat{c_p}(z)] &= E_Y \left[c_p(z) - \sum_i w_i Y_i \right] \\ &= c_p(z) - z \frac{\sum_i c_p(p(X_i)) K_{\delta}[p(X_i), z)]}{\sum_i p(X_i) K_{\delta}[p(X_i), z]} \\ &= \frac{\sum_i [p(X_i) c_p(z) - z c_p(p(X_i))] K_{\delta}[p(X_i), z])}{\sum_i p(X_i) K_{\delta}[p(X_i), z]} \\ &\sum_i w_i \frac{B(X_i, z)}{z} \end{split}$$

as required.

Remark 2. This enables straightforward evaluation of bounds on bias given bounds on the form of c_p . The estimator $\hat{c_p}$ is unbiased if $c_p(x) = kx$ for some k, since $B(X_i, z) \equiv 0$.

Remark 3. An alternative way to draw a kernelised calibration curve is to simply plot a parametric curve

which, for each t, is an only-slightly biased estimate of some point $z, c_p(z)$. If a rectangular kernel is used, this is equivalent to binning values of $p(X_i)$ [Bröcker and Smith, 2007]. However, this method does not generally give a curve across the entire range of $p(X_i)$.

It is straightforward to estimate

$$\operatorname{var}(c_{p}(z) \mid \{X_{1}, X_{2}...X_{n}\}) = \operatorname{var}\left(z \frac{\sum_{i} Y_{i} K_{\delta}[p(X_{i}), z]}{(\sum_{i} p(X_{i}) K_{\delta}[p(X_{i}), z])} \mid X_{1}, X_{2}..X_{n}\right)$$

$$= \operatorname{var}(\sum_{i} w_{i} Y_{i} \mid \{X_{1}, X_{2}..X_{n}\})$$

$$= \sum_{i} w_{i}^{2} \operatorname{var}(Y_{i} \mid X_{1}, X_{2}, ..X_{n})$$

$$\approx \sum_{i} w_{i}^{2} p(X_{i})(1 - p(X_{i}))$$

where the approximation is exact if $c_p(z) = z$. Together with an estimate of maximum absolute bias b_z at z, this enables estimates of conservative confidence intervals on $\hat{c_p}(z)$ at level $1 - \alpha$:

$$\hat{c_p}(z) \pm \left(b_z + \Phi^{-1}\left(\frac{\alpha}{2}\right) \operatorname{SE}(c_p(z)|X_i)\right)$$
(16)

In all plots in this paper, we bounded bias under the assumption that there existed k such that $|c_p(z) - kz| < z^2/10$.

The calibration estimator derived here is demonstrated in an R script $sparra_calibration.R$ available with the attached R code for this manuscript.

REFERENCES

Jochen Bröcker and Leonard A Smith. Increasing the reliability of reliability diagrams. Weather and forecasting, 22(3):651-661, 2007.

Karel GM Moons, Douglas G Altman, Johannes B Reitsma, John PA Ioannidis, Petra Macaskill, Ewout W Steyerberg, Andrew J Vickers, David F Ransohoff, and Gary S Collins. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine*, 162(1):W1–W73, 2015.

Elizbar A Nadaraya. On estimating regression. Theory of Probability & Its Applications, 9(1):141–142, 1964.

Public Health Scotland. AE2 - Accident and emergency records, 2020a. hhttps://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=3, Accessed: 6-3-2020.

Public Health Scotland. PIS - Prescribing information systems, 2020b. https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=9, Accessed: 6-3-2020.

Public Health Scotland. System Watch: urgent care usage, 2020c. https://publichealthscotland.scot/services/system-watch/#section-1-1, Accessed: 6-3-2023.

Public Health Scotland. SMR datasets - ISD Scotland Data Dictionary, 2023. https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/, Accessed: 6-3-2023.

Geoffrey S Watson. Smooth regression analysis. Sankhyā: The Indian Journal of Statistics, Series A, pages 359–372, 1964.